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A B S T R A C T
Background
Helminth infections, such as soil-transmitted helminths, schistosomiasis, onchocerciasis, and lymphatic filariasis, are prevalent in many
countries where human immunodeficiency virus (HIV) infection is also common. There is some evidence from observational studies
that HIV and helminth co-infection may be associated with higher viral load and lower CD4+ cell counts. Treatment of helminth
infections with antihelminthics (deworming drugs) may have benefits for people living with HIV beyond simply clearance of worm
infections.
This is an update of a Cochrane Review published in 2009 and we have expanded it to include outcomes of anaemia and adverse events.
Objectives
To evaluate the effects of deworming drugs (antihelminthic therapy) on markers of HIV disease progression, anaemia, and adverse
events in children and adults.
Search methods
In this review update, we searched online for published and unpublished studies in the Cochrane Library, MEDLINE, EMBASE,
CENTRAL, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICRTP), ClinicalTrials.gov, and
the WHO Global Health Library up to 29 September 2015. We also searched databases listing conference abstracts, scanned reference
lists of articles, and contacted the authors of included studies.
Selection criteria
We searched for randomized controlled trials (RCTs) that compared antihelminthic drugs with placebo or no intervention in HIV-
positive people.
1Antihelminthics in helminth-endemic areas: effects on HIV disease progression (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Data collection and analysis
Two review authors independently extracted data and assessed trials for eligibility and risk of bias. The primary outcomes were changes
in HIV viral load and CD4+ cell count, and secondary outcomes were anaemia, iron deficiency, adverse events, and mortality events.
We compared the effects of deworming using mean differences, risk ratios (RR), and 95% confidence intervals (CIs). We assessed the
quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Main results
Eight trials met the inclusion criteria of this review, enrolling a total of 1612 participants. Three trials evaluated the effect of providing
antihelminthics to all adults with HIV without knowledge of their helminth infection status, and five trials evaluated the effects of
providing deworming drugs to HIV-positive individuals with confirmed helminth infections. Seven trials were conducted in sub-
Saharan Africa and one in Thailand.
Antihelminthics for people with unknown helminth infection status
Providing antihelminthics (albendazole and praziquantel together or separately) to HIV-positive adults with unknown helminth
infection status may have a small suppressive effect on mean viral load at six weeks but the 95% CI includes the possibility of no effect
(difference in mean change −0.14 log10 viral RNA/mL, 95% CI −0.35 to 0.07, P = 0.19; one trial, 166 participants, low quality
evidence).
Repeated dosing with deworming drugs over two years (albendazole every three months plus annual praziquantel), probably has little
or no effect on mean viral load (difference in mean change 0.01 log10 viral RNA, 95% CI:−0.03 to−0.05; one trial, 917 participants,
moderate quality evidence), and little or no effect on mean CD4+ count (difference in mean change 2.60 CD4+ cells/µL, 95% CI
−10.15 to 15.35; P = 0.7; one trial, 917 participants, low quality evidence).
Antihelminthics for people with confirmed helminth infections
Treating confirmed helminth infections in HIV-positive adults may have a small suppressive effect on mean viral load at six to 12
weeks following deworming (difference in mean change −0.13 log10 viral RNA, 95% CI −0.26 to −0.00; P = 0.04; four trials,
445 participants, low quality evidence). However, this finding is strongly influenced by a single study of praziquantel treatment for
schistosomiasis. There may also be a small favourable effect on mean CD4+ cell count at 12 weeks after deworming in HIV-positive
populations with confirmed helminth infections (difference in mean change 37.86 CD4+ cells/µL, 95% CI 7.36 to 68.35; P = 0.01;
three trials, 358 participants, low quality evidence).
Adverse events and mortality
There is no indication that antihelminthic drugs impart additional risks in HIV-positive populations. However, adverse events were
not well reported (very low quality evidence) and trials were underpowered to evaluate effects on mortality (low quality evidence).
Authors’ conclusions
There is low quality evidence that treating confirmed helminth infections in HIV-positive adults may have small, short-term favourable
effects on markers of HIV disease progression. Further studies are required to confirm this finding. Current evidence suggests that
deworming with antihelminthics is not harmful, and this is reassuring for the routine treatment of confirmed or suspected helminth
infections in people living with HIV in co-endemic areas.
Further long-term studies are required to make confident conclusions regarding the impact of presumptively deworming all HIV-
positive individuals irrespective of helminth infection status, as the only long-term trial to date did not demonstrate an effect.
P L A I N L A N G U A G E S U M M A R Y
Antihelminthics in helminth endemic areas: effects on HIV infection
This Cochrane Review summarizes trials that evaluated the benefits and potential risks of providing deworming drugs (antihelminthics)
to people infected with human immunodeficiency virus (HIV). After we searched for relevant trials up to 29 September 2015 we
included eight trials that enrolled 1612 participants.
What are deworming drugs and why might they delay HIV disease progression
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Deworming drugs are used to treat a variety of human helminth infections, such as soil-transmitted helminths, schistosomiasis, on-
chocerciasis, and lymphatic filariasis. In areas where these infections are common, the World Health Organization currently recom-
mends that targeted populations are routinely treated every six to 12 months without prior confirmation of an individual’s infection
status. The use of empiric therapy, or treating all at-risk populations presumptively, is preferred to test-and-treat strategies because
deworming drugs are inexpensive and well tolerated. Additionally, a strategy of testing before treatment is considered less cost-effective
given that available diagnostic tests are relatively expensive and can exhibit poor sensitivity.
Helminth infections are known to affect the human immune system. In people with HIV, some studies have suggested that helminth
infections may reduce the number of CD4+ cells (which are a critical part of the immune response to HIV) and compromise a person’s
ability to control HIV viral replication. Thus, treatment of helminth infections could have important benefits for people living with
HIV beyond the benefits observed in the general population as a result of deworming.
What the evidence in this review suggests
Treating all HIV-positive adults with deworming drugs without knowledge of their helminth infection status may have a small
suppressive effect on viral load at six weeks (low quality evidence), but repeated dosing over two years appears to have little or no effect
on either viral load (moderate quality evidence) or CD4+ cell count (low quality evidence). These findings are based on two included
studies.
Providing deworming drugs to HIV-positive adults with diagnosed helminth infection may result in a small suppressive effect on
mean viral load at six to 12 weeks (low quality evidence) and a small favourable effect on mean CD4+ cell count at 12 weeks (low
quality evidence). However, these findings are based on small studies and are strongly influenced by a single study of praziquantel for
schistosomiasis. Further studies from different settings and populations are needed for confirmation.
Adverse events were not well reported (very low quality evidence), and trials were too small to evaluate the effects on mortality (low
quality evidence). However there is no suggestion that deworming drugs are harmful for HIV-positive individuals.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Deworming drugs compared with placebo for people with HIV and an unknown helminth infection status
Participant or population: HIV-posit ive people
Settings: urban and rural areas co-endemic for helm inths and HIV
Intervention: deworming drugs (albendazole or praziquantel or a combinat ion)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Number of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Deworming drugs
Viral load At 6 weeks after a single dose 166
(1 trial)
⊕⊕©©1,2,3,4
low
in the control group, the mean
change in viral load was an in-
crease of
0.09 log10 viral RNA
On average, with deworming,
there was a suppressive ef fect on
mean viral load of
0.14 log10 viral RNA
(0.35 benef it to 0.07 harm)
At 2 years after multiple doses 917
(1 trial)
⊕⊕⊕©1,2,5,6
moderate
In the control group, the mean
viral load increased by
0.03 log10 viral RNA
On average, with deworming,
there was a suppressive ef fect on
mean viral load of
0.01 log10 viral RNA
(0.03 benef it to 0.05 harm)
CD4+ cell count At 2 years after multiple doses 917
(1 trial)
⊕⊕©©1,2,4,5
low
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In the control group, the mean
CD4+ cell count reduced by
37.3 CD4+ cells/µL
On average, with deworming,
there was a favourable ef fect on
mean CD4+ cell count of
2.60 CD4+ cells/µL
(15.35 benef it 10.15 harm)
* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io; RNA: ribonucleic acid; HIV: human immunodef iciency virus.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1No serious risk of bias: this single trial was at low risk of select ion bias.
2No serious inconsistency: this was not applicable as there was only a single trial.
3We downgraded by 1 for serious indirectness: this single trial is based upon a specif ic sample of pregnant women treated
with albendazole or praziquantel, or both. The overall f inding of an ef fect cannot be easily generalized to all populat ions or
sett ings.
4We downgraded by 1 for imprecision: the 95% CI includes potent ially clinically important dif f erences as well as no ef fect.
Further larger studies are needed.
5We downgraded by 1 for serious indirectness: this trial was conducted in three sites in rural and urban Kenya. Helm inth
infect ion was expected to be high but was not assessed at baseline. The f indings are not easily generalized to all helm inth
endemic sett ings.
6No serious imprecision: the 95% CI includes no ef fect but is narrow around the est imate and excludes clinically important
dif f erences.
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B A C K G R O U N D
Description of the condition
Helminths, which include the soil-transmitted helminths (STH),
schistosomiasis, onchocerciasis, and lymphatic filariasis (LF), in-
fect nearly one-quarter of the world’s population (WHO 2014).
Communities with the highest helminth prevalence are often also
areas with high prevalence of human immunodeficiency virus
(HIV), and over half of HIV-positive people living in helminth
endemic areas are estimated to be co-infected with at least one
helminth infection (UNAIDS 2007).
Helminth infections have a significant effect on the human im-
mune system, and it is hypothesized that helminth infections
may modulate the host’s ability to control the HIV virus (Lawn
2001;Modjarrad 2010).More specifically, studies have shown that
amongst HIV-positive individuals with helminth co-infections.
• There may be a more rapid decline in the CD4+ T-cells
responsible for immunologic function in HIV-positive people,
and increased cellular susceptibility to HIV infection (Eggena
2005; Shapira-Nahor 1998).
• CD4+ and CD8 T-cells and monocytes may exhibit
increased expression of HIV chemokine co-receptors (Chachage
2014; Lawn 2001; Kalinkovich 1999; Kalinkovich 2001; Secor
2003).
• There may be increased suppression of the antiviral T helper
(Th)1 lymphocyte due to helminth-associated Th2 lymphocyte
propagation (Borkow 2006; Brown 2006; Kinter 2007).
• There may be higher levels of eosinophilia, increased
immunoglobulin (Ig) E levels, and stimulation of other
immunosuppressive cytokine responses (Bentwich 1996; Blish
2010).
InHIV-positive individuals, co-infectionwith helminthsmay lead
to the accelerated destruction of the host immune system and
earlier onset of acquired immunodeficiency syndrome (AIDS)-
defining illnesses and death (Nesheim 2007). Even amongst HIV-
positive patients treated with antiretroviral (ART) drugs for HIV,
helminth infections may adversely influence HIV clinical out-
comes (Ivan 2015). Given these profound effects on host immu-
nity, helminth infections have been suggested to play an impor-
tant role in the pathogenesis of HIV in Africa (Bentwich 1995;
Fincham 2003).
Description of the intervention
Current World Health Organization (WHO) guidelines recom-
mend that high-risk populations living in endemic areas partic-
ipate in regular mass drug administration with antihelminthic
medicines (deworming drugs) without the need for prior confir-
matory diagnostic testing. This is also known as preventive che-
motherapy. In settings where community prevalence of STH in-
fections exceed 20%, the WHO recommends annual treatment
with albendazole or mebendazole for all preschool-age children,
school-age children, and pregnant women in their second and
third trimester (WHO 2006).
The rationale for mass treatment rather than a test and treat ap-
proach is the safety of the drugs, low cost of the drugs (often do-
nated by pharmaceutical companies), the relatively high cost of di-
agnostic testing, and the high prevalence of infection in some areas.
The cost of these programmes is estimated to be as low asUSD0.25
per treatment, including delivery costs (Bundy 2009; Partnership
for Child Development 1998). Mass deworming programs are
scaling up rapidly in part due to theWHONTDRoadmap for Im-
plementation and the 2012WHO-endorsed LondonDeclaration,
which calls for the control or elimination of 10 neglected tropical
diseases including STHs, schistosomiasis, LF, and onchocerciasis
by 2020 (Uniting to Combat NTDs 2012).
In research settings deworming treatment may require prior con-
firmatory testing or treatment may be delivered empirically as
customary in preventative chemotherapy campaigns. For exam-
ple, specific age groups may be targeted and recruited to receive
deworming medications during community-based household re-
cruitment, at HIV clinics, at tuberculosis (TB) clinics, or during
antenatal care.
How the intervention might work
If helminth co-infection plays a significant detrimental role in
HIV disease progression it is possible that effective treatment or
prevention of helminth infections could slow the progression of
HIV (Kallestrup 2005 ZWE; Wolday 2002). Relatively modest
increases in viral load (0.3 to 0.5 log10 copies/mL)may increase the
annual risk of progression to an AIDS-defining illness or death by
as much as 25% to 44% (Modjarrad 2008). Mathematical mod-
elling suggests that a reduction in HIV-1 ribonucleic acid (RNA)
levels of 0.5 log10 copies/mL could slow the onset of AIDS by 3.5
years and could delay the need for ART medications by almost
a full year (Gupta 2007). The potential increases in HIV RNA
associated with helminth co-infection suggest that for every 100
HIV-positive individuals with an STH infection in sub-Saharan
Africa, there could be 3.1 (95% CI: 0.1 to 14.9) excess HIV-1
transmission events. The trend is similar for other helminth in-
fections, with 8.5 (95% CI 0.2 to 38.6) excess HIV transmission
events attributed to schistosomiasis and 13.3 (95%CI 0.3 to 89.2)
to filariasis (Baggaley 2015).
Observational studies of the effects of deworming drugs on mark-
ers of HIV disease progression have had conflicting results. Several
studies have noted delays in HIV disease progression following de-
worming (Brown 2005; Ivan 2015; Lankowski 2014; Mulu 2013;
Muok 2013; Wolday 2002 ), while others have reported no as-
sociation (Brown 2004; Elliott 2003; Hosseinipour 2007; Kleppa
2014; Lawn 2000; Modjarrad 2005). In the previous version of
this systematic review we found some evidence from randomized
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controlled trials of short term benefits with deworming but also
the need for further larger studies (Walson 2009).
Why it is important to do this review
Given that a substantial number of individuals targeted by
helminth control programmes may be exposed to or infected with
HIV, it is important to establish the safety of deworming drugs in
HIV-positive populations and the potential for drug interactions,
particularly as an increased incidence of drug reactions has been
observed in patients with advanced HIV infection (Gordin 1984;
Nunn 1991). Available data from a recent systematic review also
suggested the potential for an interaction between both meben-
dazole and albendazole and nucleoside reverse transcriptase in-
hibitors appears low, although no formal pharmacokinetic studies
exist. The review also reported that interactions may exist between
praziquantel and protease inhibitors via enzyme inhibition (Seden
2013).
Since the publication of our initial Cochrane Review of this topic
in 2009 (Walson 2009), deworming campaigns have been dra-
matically scaled up and it has become increasingly important to
understand not only the effects of deworming on HIV disease
progression but also the safety of treating these unique patient
populations. In this update, we have expanded the scope of this
Cochrane Review to include trials that evaluate the impact of de-
worming on anaemia and iron deficiency, as well as markers of
HIV disease progression and safety.
O B J E C T I V E S
To evaluate the effects of deworming drugs (antihelminthic ther-
apy) on markers of HIV disease progression, anaemia, and adverse
events in children and adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) or quasi-RCTs.
Types of participants
Adults and children (older than one year of age) infected with hu-
man immunodeficiency virus (HIV)-1 or HIV-2 with and with-
out documented helminth co-infection.
Relevant helminth-infections included schistosomiasis (Schis-
tosomiasis mansoni and Schistosomiasis haematobium), STH
(Strongyloides stercoralis, Ancylostoma duodenale,Necator ameri-
canus, Trichuris trichiura, Ascaris lumbricoides, and Trichostrongy-
lus), lymphatic filariasis (LF) (Wuchereria bancrofti,Brugia malayi,
andBrugia timori), onchocerciasis (Onchocerca volvulus), and other
filariasis (Mansonella streptocerca).
For trials that included both HIV-positive and uninfected partic-
ipants, we contacted the trial authors and requested data relevant
to the HIV-positive participants only.
Types of interventions
Intervention
Any antihelminthic drug therapy recommended by World Health
Organization (WHO) guidelines for use in the eradication of
helminth infections in humans. This included the benzimidazoles
(albendazole or mebendazole), ivermectin, praziquantel, diethyl-
carbamazine (DEC), bithionol, oxamniquine, pyrantel, and nita-
zoxanide (WHO 2006).
Control
Placebo or no treatment. For the outcome of adverse events, we
also considered alternative antihelminthic drugs.
Types of outcome measures
Primary outcomes
• Change in plasma viral load (log10copies viral RNA/mL).
• Change in CD4+ T-cell count (cells/µL).
Secondary outcomes
• Change in CD8+ T-cell count (cells/µL).
• CD4+/CD8+ T-cell ratio.
• Adverse events associated with antihelminthic therapy (if
reported in the included trials).
• Iron deficiency (as defined by the trial authors, based on a
biomarker of iron status and tests, at 34 weeks gestation or later
in pregnant populations).
• Anaemia (defined as haemoglobin (Hb) below 110 g/L,
adjusted for altitude and smoking as appropriate).
• Death.
Search methods for identification of studies
Electronic searches
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In coordination with a the Information Specialist of the Cochrane
Infectious Diseases Group (CIDG), we searched MEDLINE on-
line (1980 to 2015), EMBASE (1980 to 2015), CENTRAL (1980
to 2015), the World Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP) (all dates), and clini-
caltrials.gov (1980 to 2015) using the strategies documented in
Table 1, Table 2, Table 3, Table 4, and Table 5, respectively.
As this is a review update, we also searched MEDLINE, EM-
BASE, CENTRAL, and AIDSEARCH databases using the exact
search terms utilized in the previously published in Walson 2009
up to 29 September 2015 (Table 6; Table 7; Table 8; Table 9).
We conducted a separate search in the WHO Global Health Li-
brary, which accesses AIM (AFRO), LILACS (AMRO/PAHO),
IMEMR (EMRO), IMSEAR (SEARO), WPRIM (WPRO),
WHOLIS (KMS), and SciELO resources (Table 10).
We did not apply any language or date restrictions.
Searching other resources
Reference lists
We examined all references cited by included trials to identify any
further studies for inclusion.
Data collection and analysis
Selection of studies
Two review authors (ARM and PB) independently read the titles,
abstracts, and descriptor terms of all downloaded material from
the electronic searches and discarded any irrelevant reports. When
there was uncertainty as to the relevance of the study, we main-
tained the citation for further review. Two review authors (ARM
and PB) then independently evaluated the full-text articles of all
identified citations to establish relevance of the article according
to the pre-specified criteria.
We reviewed the studies for relevance based on study design, types
of participants, exposures, and outcome measures. ARM and PB
independently applied the inclusion criteria for this Cochrane Re-
view update. There were three differences that required a third
review author (JW) to resolve.
Data extraction and management
Two review authors (ARM and PB) independently extracted data
from the included trials using standardized data extraction forms
for randomized trials, as detailed in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
We extracted the following characteristics from each included trial.
• Administrative details: identification; author(s); published
or unpublished; year of publication; year in which study was
conducted; funding source.
• Details of study: study design; randomization method;
duration; completeness of follow-up; country and location of the
study; setting (for example, urban or rural, hospital or clinic);
method(s) of recruitment; number of participants by trial arm.
• Characteristics of participants: age; gender; socioeconomic
status; HIV clinical staging (if available); antiretroviral (ART)
status.
• Details of intervention: medication; dose; duration;
number of treatments; control group.
• Details of outcomes: primary outcome; unit of
measurement; change in viral load; change in CD4+ count;
change in rate of clinical HIV disease progression (changes in the
WHO or Centers for Disease Control and Prevention (CDC)
staging); nutritional indicators; adverse events; mortality.
Assessment of risk of bias in included studies
Two review authors (ARM and PB) independently evaluated
the methodological quality of included clinical trials using the
Cochrane ’Risk of bias’ assessment tool described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We followed the guidance to assess whether adequate steps were
taken to reduce the risk of bias across five domains: sequence
generation; allocation concealment; blinding of participants and
personnel; blinding of outcome assessors; and incomplete outcome
data.
For sequence generation and allocation concealment, we reported
themethods used. For blinding,we describedwhowas blinded and
the blinding method. For incomplete outcome data, we reported
the percentage andproportionof participants lost to follow-up.We
categorized our ’Risk of bias’ judgements as either ’low’, ’high’, or
’unclear’. Where risk of bias was unclear, we attempted to contact
the trial authors for clarification and resolved any differences of
opinion through discussion.
Measures of treatment effect
We summarized dichotomous outcomes using risk ratios (RR)
with 95% confidence interval (CIs). We summarized continuous
outcomes using mean differences with 95% CIs. For some studies
we utilized only data from HIV-positive participants and the trial
authors provided the raw data accordingly.
HIV disease progression is associated with a decline in CD4+
cell counts and an increase in viral load. A favourable effect of
deworming drugs on CD4+ cell count therefore refers to either
a larger increase in CD4+ cell count or a smaller depletion in
CD4+ cell count. A suppressive effect on viral load refers to either
a reduction in viral load, or a smaller increase in viral load.
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Unit of analysis issues
For trials with repeat outcome measurements over time, we uti-
lized and reported the study’s final outcome measure reflecting the
whole follow-up time for each individual participant. For studies
with 2 x 2 factorial designs in which there were more than one
treatment group we chose not to combine experimental interven-
tion groups into a single group and risk loss of information re-
garding the effects of different antihelminthic treatments. Rather,
we chose to present the interventions separately and divide the
total number of participants in the control group to account for
multiple comparisons in meta-analyses. The means and standard
deviations were left unchanged as recommended in Section 16.5.4
of the Cochrane Handbook (Higgins 2011). This method only
partially overcomes the unit-of-analysis error (because the result-
ing comparisons remain correlated).However, an advantage of this
approach is that it allows for investigations of heterogeneity across
intervention arms.
Dealing with missing data
We contacted trial authors where there were missing or unclear
data.We consideredmissingdata resulting from losses to follow-up
to be missing at random unless there were indications otherwise.
Assessment of heterogeneity
We assessed heterogeneity amongst trials by inspecting the forest
plots (to detect overlapping CIs) and the I² statistic with a level
of 50% to denote moderate levels of heterogeneity, as well as by
applying the Chi² test with a P value of 0.10 to indicate statistical
significance, as described in Section 9.5.2 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011).
Assessment of reporting biases
We could not perform an assessment of the likelihood of reporting
bias due to an insufficient number of included trials.
Data synthesis
We pooled the results from included RCTs in six different meta-
analyses, using a random-effects method, due to the heterogeneity
of the interventions (DerSimonian 1986). We performed pooled
meta-analyses to assess the outcomes of change in mean plasma
viral load in populations with unknown helminth infection status,
change in mean CD4+ cell count in populations with unknown
helminth infection status, change in mean plasma viral load in
helminth-infected populations only, change in mean CD4+ cell
count in helminth-infected populations only, difference in adverse
events, and difference in mortality events.
We assessed the quality of evidence by outcome using the Grad-
ing of Recommendations Assessment, Development and Evalu-
ation (GRADE) approach. We used GRADEprofiler Guideline
Development Tool (GDT) software (GRADEpro GDT 2015) to
import data from Review Manager (RevMan) (RevMan 2014) to
create three ’Summary of findings’ tables. For each of the review
outcomes we created a summary of the intervention effect and a
measure of quality using the GRADE approach whereby the qual-
ity of evidence received a grade of either ’very low’, ’low’, ’mod-
erate’, or ’high’, by outcome. We assessed the quality of the evi-
dence based on five criteria: risk of bias, imprecision, indirectness,
inconsistency, and publication bias.
Subgroup analysis and investigation of heterogeneity
We conducted subgroup analyses with respect to trials in which
participants had confirmed helminth infections, as well as trials in
which participants had unknown infection status. We planned to
investigate statistical heterogeneity by conducting subgroup anal-
ysis with respect to antihelminthic treatment used, participant age,
ARV initiation status, and geographic location.However, we could
not do so because of the limited number of studies included for
meta-analyses.
Sensitivity analysis
We assessed the robustness of the results by conducting a sensitivity
analysis against the ’Risk of bias’ criteria.
R E S U L T S
Description of studies
Results of the search
In thisCochraneReviewupdate, we identified 312 references using
the CIDG Information Specialist’s search criteria described above
and an additional 1936 unique references by applying the search
criteria utilized in the 2009 Cochrane Review (Walson 2009).
Of the 2248 citations screened, we excluded 2203 citations due
to irrelevance to antihelminthics, no inclusion of HIV-positive
participants, or both. We retrieved and formally reviewed 42 full-
text articles for eligibility (see Figure 1 for the study flow diagram).
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Figure 1. Study flow diagram.
Included studies
Eight randomized controlled trials (RCTs) met the inclusion cri-
teria of this Cochrane Review. Three were included in the 2009
version of this Cochrane Review (Kallestrup 2005 ZWE; Nielsen
2007 TZA;Walson 2008 KEN) and we added five new trials, due
to more recent publication dates or the expanded scope of the
protocol (Abate 2014 ETH; Kelly 1996 ZMB; Suputtamongkol
2011 THA; Walson 2012 KEN; Webb 2012 UGA).
Seven trials were conducted in sub-Saharan Africa, and one in
Thailand (Suputtamongkol 2011 THA). All eight trials included
adults infected with HIV-1 or HIV-2, and one trial was limited to
pregnant adult women (Webb 2012 UGA). One small trial from
Zambia recruited only adults with chronic diarrhoea (Kelly 1996
ZMB). There were no trials in preschool or school-age children.
The RCTs aimed to evaluate a range of primary outcomes:
changes in tuberculosis (TB) morbidity factors (Abate 2014
ETH), diarrhoea duration (Kelly 1996 ZMB), clearance of
Strongyloides infection (Suputtamongkol 2011 THA), CD4+/
CD8+ cell ratios (Nielsen 2007 TZA), CD4+ cell count (
Kallestrup 2005 ZWE; Nielsen 2007 TZA; Walson 2008 KEN;
Walson 2012 KEN), and HIV-1 RNA viral load (Kallestrup
2005 ZWE; Nielsen 2007 TZA; Walson 2008 KEN; Walson
2012 KEN; Webb 2012 UGA).
In two trials, HIV-positive participants were not taking antiretro-
viral (ART) drugs (Walson 2008 KEN; Walson 2012 KEN), in
one trial ART use was limited to prevention of mother-to-child
transmission of HIV (Webb 2012 UGA), and in one trial ART
use was very high (Abate 2014 ETH). Four trials did not spec-
ify if the HIV-positive individuals were currently taking ART
(Kallestrup 2005 ZWE; Kelly 1996 ZMB; Nielsen 2007 TZA;
Suputtamongkol 2011 THA).
Three trials evaluated deworming drugs provided presumptively
to participants with unknown helminth infection status: Walson
2012KENadministered albendazole (400mg) every threemonths
and praziquantel (40 mg/kg) annually for two years; Webb 2012
UGA administered either albendazole (800 mg), praziquantel (40
mg/kg), or both to pregnant women and followed up for six weeks
and at delivery; and Kelly 1996 ZMB administered albendazole
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(800mg) twice daily for twoweeks to adultswith chronic diarrhoea
(see Table 11 and Table 12).
Five RCTs treated HIV-positive adults with confirmed helminth
infections; two trials treated soil-transmitted helminth (STH) in-
fectionswith albendazole (400mg) once daily for three days (Abate
2014 ETH; Walson 2008 KEN), one study treated schistosomi-
asis with praziquantel (40 mg/kg) once only (Kallestrup 2005
ZWE), one study treated STH or schistosomiasis with alben-
dazole, praziquantel, or both (Webb 2012 UGA), and one trial
treated lymphatic filariasis (LF) with diethylcarbamazine (DEC)
(Nielsen 2007 TZA). These trials followed participants for six to
12 weeks (see Table 13 and Table 12).
Five trials measured and reported HIV-1 RNA viral load (
Kallestrup 2005 ZWE; Nielsen 2007 TZA; Walson 2008 KEN;
Walson 2012 KEN; Webb 2012 UGA), and four trials reported
CD4+ cell count (Kallestrup 2005 ZWE; Nielsen 2007 TZA;
Walson 2008 KEN; Walson 2012 KEN). One study reported
CD4+/CD8+ cell ratio, seven trials reported adverse events, one
trial reportedmeasures of iron deficiency and anaemia respectively,
and six trials reported mortality.
We requested unpublished data from all but one trial author (Kelly
1996 ZMB), and we included these data in the analyses.
Excluded studies
We excluded 33 studies due to their observational designs or ir-
relevance to the intervention or outcomes of interest. See the
’Characteristics of excluded studies’ table. We identified two on-
going or planned RCTs, and have provided descriptions of these
trials in Table 14.
Risk of bias in included studies
We have presented a summary of our ’Risk of bias’ assessments in
Figure 2 and Figure 3.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included trial.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each methodological quality item
presented as percentages across all included trials.
Allocation
Five trials adequately described both random sequence generation
and allocation concealment and we judged them at low risk of
selection bias (Abate 2014 ETH; Suputtamongkol 2011 THA;
Walson 2008 KEN; Walson 2012 KEN; Webb 2012 UGA). One
trial did not describe allocation concealment and was at unclear
risk of selection bias (Nielsen 2007 TZA), and one stated that allo-
cation was ’open’ and was at high risk of selection bias (Kallestrup
2005 ZWE). All included trials appeared to have similar reported
baseline characteristics between randomization groups.
Blinding
Five trials used placebos and we judged them to be at low risk
of performance bias (systematic differences between groups in the
care that is provided, or in exposure to factors other than the
interventions of interest) (Abate 2014 ETH; Kelly 1996 ZMB;
Nielsen 2007 TZA; Walson 2008 KEN; Webb 2012 UGA). We
judged the remaining trials to be at high risk of performance bias
(Kallestrup 2005 ZWE; Suputtamongkol 2011 THA; Walson
2012 KEN). In addition, individual participants who received
more frequent treatment doses hadmore opportunities to interface
with health facilities as an inherent aspect of the intended trial
design and may have non-differentially had access to improved
care.
Only two trials adequately described blinding of outcomes assess-
ment to prevent detection bias (Abate 2014 ETH;Kallestrup 2005
ZWE). The remaining trials were at unclear risk of bias. Two trials
utilized diagnostic methods with low sensitivity, such as duplicate
Kato-Katz from a single stool sample (Walson 2008 KEN; Webb
2012 UGA), which might affect the total sample size of helminth-
infected participants, but not the fidelity of the intervention or
outcome measures.
Incomplete outcome data
Attrition bias may have been an issue in one included trial, Nielsen
2007 TZA, where there appeared to be differential loss to follow-
up between the groups. In addition, two trials reported that less
than 80% of the established participant cohort were followed-up
(Kallestrup 2005 ZWE; Kelly 1996 ZMB), although Kallestrup
2005 ZWE reported that reasons for study drop-out were evenly
distributed,with the exceptionof a single groupwhich had ahigher
number of losses to follow-up due to migration.
Selective reporting
We could not perform an assessment of the likelihood of reporting
bias due to an insufficient number of included trials.
Five trials performed and reported an intention-to-treat analysis
(Abate 2014 ETH; Kallestrup 2005 ZWE; Walson 2008 KEN;
Walson 2012 KEN; Webb 2012 UGA). The three remaining
trials performed outcome comparisons only for participants for
whom follow-up data were available or relevant (Kelly 1996 ZMB;
Nielsen 2007 TZA; Suputtamongkol 2011 THA).
13Antihelminthics in helminth-endemic areas: effects on HIV disease progression (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Effects of interventions
See: Summary of findings for themain comparison Summary of
findings for participants with unknown helminth infection status;
Summary of findings 2Summary of findings for participants with
confirmed helminth infections; Summary of findings 3 Summary
of findings for secondary outcomes
Comparison: antihelminthic drugs versus placebo or
no intervention
Primary outcomes: markers of HIV disease progression
Participants with unknown helminth infection status
Two trials evaluated the effects of antihelminthic drugs versus
placebo on HIV disease progression amongst HIV-positive adults
in sub-Saharan Africa with unknown helminth infection status.
One trial administered either albendazole (800 mg), praziquantel
(40 mg/kg), or both, to pregnant women and followed up for six
weeks (Webb 2012UGA), and one administered albendazole (400
mg) every three months and praziquantel (40 mg/kg) annually for
two years (Walson 2012 KEN).
Viral load
In the single included trial of pregnant women, the mean viral
load at six weeks was lower with each of the interventions, but the
confidence intervals (CIs) included the possibility of no difference
(difference inmean change−0.14 log10 viral RNA, 95%CI−0.35
to 0.07; P = 0.19, one trial, 166 participants, Analysis 1.1).
In the larger trial from Kenya, there was no substantial difference
inmean change in viral load between treatment and control groups
after two years of repeated drug administration (difference inmean
change 0.01 log10 viral RNA, 95% CI −0.03 to 0.05; P = 0.66,
one trial, 917 participants, Analysis 1.1).
CD4+ cell count
Only the long-term trial from Kenya reported mean change in
CD4+ cell counts. There was no substantial difference in mean
change in CD4+ count between the treatment and control groups
over two years of repeated drug administration (difference inmean
change 2.60 cells/µL/year, 95% CI−10.15 to 15.35; P = 0.7, one
trial, 917 participants, Analysis 1.2).
Participants with confirmed helminth infections
Five trials treated HIV-positive adults known to be infected with
helminths; two trials treated STH infection with albendazole (400
mg) once daily for three days (Abate 2014 ETH; Walson 2008
KEN), one trial treated schistosomiasis with praziquantel (40 mg/
kg) once only (Kallestrup 2005 ZWE), and one trial treated LF
with DEC (Nielsen 2007 TZA). These trials reported these out-
comes at 12 weeks. One trial also provided outcome data at six
weeks for participants infected with schistosomiasis and STHs
(Webb 2012 UGA).
Viral load
In a pooled analysis across four trials with different helminth in-
fections and different drug regimens, there was an overall suppres-
sive effect on viral load after six to 12 weeks in the intervention
groups compared to controls (difference in mean change −0.13
log10 viral RNA, 95% CI −0.26 to −0.00; P = 0.04, four trials,
445 participants, Analysis 2.1). However the CIs of the individual
trials are wide and the CIs of all but one trial, Kallestrup 2005
ZWE, included the possibility of no effect. In this trial of HIV and
schistosomiasis co-infected participants, those treated with praz-
iquantel had little change in mean plasma viral load at 12 weeks
(−0.001 log10 viral RNA), while the mean viral load substantially
increased in the untreated group (0.21 log10 viral RNA, P = 0.03).
This trial was at high risk of selection bias, and exclusion of this
trial broadens the CI of the pooled estimate to allow the possibility
of no difference.
CD4+ cell count
In three trials mean CD4+ cell count declined in both treated
and control groups over 12 weeks, with a smaller decrease in the
treated groups (Analysis 2.2). However in one trial of TB-infected
individuals who initiated both TB treatment and ART at baseline,
CD4+ cell counts increased in both treated and control groups
with a larger increase in those treated with deworming drugs (dif-
ference inmean change 43.00 cells/µL, 95%CI 1.14 to 84.86; one
trial, 208 participants). In the pooled analysis, the average change
in CD4+ cell count was more favourable in the group treated with
deworming drugs, and the CI excludes the possibility of no effect
(difference in mean change 37.86 cells/µL, 95% CI 7.36 to 68.35;
P = 0.01; three trials, 358 participants, Analysis 2.2).
Nielsen 2007 TZA presented results as declines in CD4+ per cent,
and thus we did not include the results in the pooledmeta-analysis
(Analysis 2.2).
Secondary outcomes
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Adverse events
Seven trials commented on adverse events, of which five reported
that no adverse events occurred (Abate 2014 ETH; Nielsen 2007
TZA; Suputtamongkol 2011 THA; Walson 2008 KEN; Webb
2012 UGA).
Kelly 1996 ZMB administered albendazole twice daily for two
weeks to adults with chronic diarrhoea, and reported seven adverse
events in the treatment group and three in the control group. Of
the seven adverse events with albendazole, one participant had a
cutaneous reaction that resolved within one week of discontinuing
the drug, and four complained of dizziness, headache, cough, and
difficulty swallowing. The trial authors noted that the symptoms
were indistinguishable from symptoms of the underlying illness.
Walson 2012 KEN administered praziquantel annually and alben-
dazole every three months for two years, and reported 16 severe
adverse events in the treatment group and 18 in the control group.
The trial authors determined that none of the adverse events were
directly related to the study drug.
The pooled analysis of these two trials does not suggest a signif-
icant increase in relative risk for adverse events in HIV-positive
individuals who receive antihelminthics relative to those who do
not (RR 1.23, 95% CI 0.53 to 2.83; P = 0.63, seven trials, 1649
participants, Analysis 3.2).
Mortality
Six included trials recorded mortality events, of which five trials
observed at least one death (Abate 2014 ETH; Kelly 1996 ZMB;
Suputtamongkol 2011 THA; Walson 2008 KEN; Walson 2012
KEN). In the pooled analysis, treatment was associated with a
point estimate of a 33% reduction in mortality, but the CIs in-
cluded no effect (RR 0.77, 95% CI 0.52 to 1.14; P = 0.19, five
trials, 1627 participants, Analysis 3.3). Most deaths occurred in
the oldest study where participants were chronically unwell (had
chronic diarrhoea) and were probably not on ART (Kelly 1996
ZMB). None of the deaths appeared to be directly associated with
the antihelminthic interventions, as reported by the trial authors.
Anaemia and iron deficiency
Only one trial captured data regarding changes in serum haemo-
globin levels (Kallestrup 2005 ZWE). The trial authors reported a
mean difference in haemoglobin of −0.25 g/dL (95% CI −0.58
to −0.08) in the HIV-positive participants that received prazi-
quantel relative to the untreated participants over three months
follow-up (unpublished data).
A secondary analysis of the primary Nielsen 2007 TZA trial ex-
amined the effect of antihelminthic treatment on micronutrient
indicators in LF and HIV co-infected individuals (Nielsen 2009).
The study found that serum ferritin levels increased in co-infected
individuals 12 weeks after treatment. The study authors observed
a log mean increase of 0.07 µg/L in the treatment group, while
they noted a log mean increase of 0.04 µg/L in the non-treated
group. The mean difference in log ferritin levels between baseline
and 12 weeks follow-up in the treated group relative to the control
group was thus 0.03 µg/L (95% CI −0.30 to 0.35) (unpublished
data provided by the study authors). As the study authors did not
observe the same increase in ferritin in the HIV-positive LF-un-
infected groups, the study authors hypothesize that the serum fer-
ritin changes may be related to the immune mechanisms involved
in killing of filaria.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Deworming drugs compared with placebo for people with HIV and confirmed helminth infections
Participant or population: HIV-posit ive people with proven helm inth infect ion
Settings: urban and rural areas co-endemic for helm inths and HIV
Intervention: deworming drugs (albendazole, praziquantel, albendazole and praziquantel, or diethylcarbamazine)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Number of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Deworming drugs
Viral load At 6 to 12 weeks 445
(4 trials)
⊕⊕©©
low1,2,3,4
In the control groups, the mean
change in viral load ranged f rom
a 0.13 decrease to an increase of
0.21 log10 viral RNA
On average, with deworming,
there was a small suppressive ef -
fect on mean viral load of
0.13 log10 viral RNA
(0.26 benef it to 0.00 benef it )
CD4+ cell count At 6 to 12 weeks 358
(3 trials)
⊕⊕©©
low2,5,6,7
In the control groups, the mean
change in CD4+ cell count ranged
f rom
a decrease of 68 to an increase
of 45 CD4+ cells/µL
On average, with deworming,
there was favourable ef fect on
mean CD4+ cell count of
37.86 CD4+ cells/µL
(7.36 benef it to 68.35 benef it )
* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io; RNA: ribonucleic acid; HIV: human immunodef iciency virus.
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1We downgraded by 1 for serious risk of bias: of the f ive studies, only one had CIs that excluded the possibility of no ef fect
and this study was at high risk of select ion bias.
2No serious inconsistency: stat ist ical heterogeneity was low.
3We downgraded by 1 for serious indirectness: the only trial f or which the CIs excluded the possibility of no ef fect administered
praziquantel to people with schistosomiasis. The overall f inding of an ef fect cannot be easily generalized to all deworming
drugs, helm inth infect ions, or sett ings.
4No serious imprecision: the overall 95% CI is wide and includes both clinically important ef fects and no ef fect. However, as
potent ial harm is excluded, we did not further downgrade the evidence.
5No serious risk of bias: one trial was at high risk of select ion bias, but excluding this trial did not substant ially change the
result .
6We downgraded by 1 for serious indirectness: the included trials are f rom a very lim ited number of sett ings and part icipants.
The overall f inding is not easily generalized to all deworming drugs, helm inth infect ions, or sett ings, and further trials are
needed.
7We downgraded by 1 for imprecision: the 95% CI is wide and includes potent ially clinically important dif f erences as well as
no ef fect. Further larger studies are needed.
1
7
A
n
tih
e
lm
in
th
ic
s
in
h
e
lm
in
th
-e
n
d
e
m
ic
a
re
a
s:
e
ffe
c
ts
o
n
H
IV
d
ise
a
se
p
ro
g
re
ssio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
Deworming drugs compared with placebo for people with HIV and both known and unknown helminth infection status
Participant or population: HIV-posit ive people
Settings: urban and rural areas co-endemic for helm inths and HIV
Intervention: deworming drugs (albendazole, praziquantel, albendazole and praziquantel, or diethylcarbamazine)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Albendazole
Iron deficiency (serum fer-
ritin)
log10 mean increase of 0.04
µg/ L
log10 mean increase of 0.07
µg/ L
Deworming drugs associ-
ated with a 0.03 higher µg/ L
log10 mean ferrit in measure
(0.30 lower to 0.35 higher)
16
(1 trial)
⊕©©©1,2,3,4
very low
Anaemia (serum haemo-
globin)
Increase in 0.15 g/ dL Decrease in 0.10 g/ dL Deworming drugs associ-
ated with a 0.25 lower g/ dL
haemoglobin
(0.58 lower to 0.08 higher)
130
(1 trial)
⊕©©©2,4,5,6
very low
Mortality 41 per 1000 52 per 1000 RR 0.77
(0.52 to 1.14)
1627
(5 trials)
⊕⊕©©7,8,9,10
low
Adverse events 32 per 1000 35 per 1000 RR 1.23
(0.53 to 2.83)
1649
(7 trials)
⊕©©©4,9,11,12
very low
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RR: risk rat io; HIV: human immunodef iciency virus.
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1No serious risk of bias: this single trial was at risk of select ion bias. However, the outcome is an object ive laboratory
measure. We did not downgrade the quality of the evidence.
2No serious inconsistency: not applicable as this is a single trial.
3We downgraded by 2 for serious indirectness: this single trial is based upon a very small sample size of people treated with
diethylcarbamazine for lymphatic f ilariasis. The overall f inding of an ef fect can not be easily generalized to all deworming
drugs, helm inth infect ions, or sett ings.
4We downgraded by 1 for imprecision: the 95% CI is wide and includes potent ially clinically important dif f erences as well as
no ef fect. Larger studies are needed.
5We downgraded by 1 for serious risk of bias: this single trial was at high risk of select ion bias.
6Downgraded by 1 for serious indirectness: this single trial is based upon a very small sample size of people treated with
praziquantel for schistosomiasis. The overall f inding of an ef fect can not be easily generalized to all deworming drugs or
helm inth infect ions or sett ings.
7No serious risk of bias: although some of the trials are at risk of select ion bias the outcome is an object ive measure. We did
not downgrade the evidence.
8No serious inconsistency: stat ist ical heterogeneity was low.
9No serious indirectness: these trials took place in dif f erent sett ings, with dif f erent drugs, and with dif f erent helm inth
infect ions present. However, ef fects of treatment were consistent across the trials.
10We downgraded by 2 for imprecision: the 95% CI is wide and includes potent ially clinically important dif f erences as well as
no ef fect. Addit ionally the trials were not powered to detect changes in the rare outcome of mortality. A trial in which 3% of
controls died would require a sample size of 7648 part icipants to attain 80% power to detect a 33% reduct ion in mortality.
11We downgraded by 2 for serious risk of bias: it is unclear how some of the trial authors def ined adverse events and thus
there is risk of bias in outcome assessment.
12No serious inconsistency: however, the analysis has an I² stat ist ic value of 34%, which may represent low to moderate
heterogeneity.
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D I S C U S S I O N
Summary of main results
In human immunodeficiency virus (HIV)-infected antiretroviral
(ART)-naive adults with unknown helminth infection status, pro-
vision of deworming drugs (albendazole and praziquantel together
or separately) may have a small suppressive effect on viral load at
six weeks. However, these data come from a small single trial and
the 95% confidence interval (CI) includes the possibility of no
effect (low quality evidence). Repeated dosing over two years ap-
pears to have little or no effect in HIV-positive ART-naive adults
(moderate quality evidence).
Treating helminth infections in HIV-positive individuals with
confirmed helminth infections may have a small suppressive ef-
fect on mean viral load at six to 12 weeks (low quality evidence).
However, this finding is strongly influenced by a single study of
praziquantel for schistosomiasis and further studies from different
settings and populations are needed for validation. There may also
be a small favourable effect on mean CD4+ cell count at 12 weeks.
Most of the included trials did not consistently or rigorously re-
port adverse events (very low quality evidence) and trials were un-
derpowered to evaluate effects on mortality (low quality evidence).
However, there is no indication of excessive risk associated with
deworming HIV-positive populations.
Overall completeness and applicability of
evidence
Despite the publication of five new RCTs since the previous edi-
tion of this Cochrane Review, Walson 2009, there is still insuf-
ficient evidence to make definitive conclusions about the effects
of deworming drugs on markers of HIV disease progression. The
eight trials included evaluate different drugs used to treat differ-
ent helminth infections, which limits our ability to make broad
generalizations.
For preventive chemotherapy programmes, in which deworming
drugs are provided presumptively to all individuals, this Cochrane
Review includes only two relevant trials and only one that reported
long-term effects. In the short-term trial there is a suggestion of a
short-term benefit to deworming, however the trial is too small to
prove an effect. Similarly, while the single long-term trial found no
evidence of benefit, further trials from other settings with different
helminth endemicities are necessary before the possibility of long-
term beneficial effects can be fully excluded.
Only short-term evidence is available when we limit the analysis
to HIV-positive adults with confirmed helminth infections. The
finding of a suppressive effect on viral load in this group is highly
reliant on a single trial of praziquantel for schistosomiasis. While
the effect estimate of the pooled analysis is small (−0.13 log10),
mathematical modelling exercises estimate that a decrease in vi-
ral load of 0.3 log10 in heterosexual couples could decrease HIV
transmission by an average of 20% and AIDS-related illnesses or
death by 25% (Modjarrad 2008).
It is also important tonote that none of the trials included children,
and only one trial included a significant number of people taking
ART (Abate 2014 ETH). These are therefore important groups
for further research.
While overall few adverse events were reported in the included
trials (23 in total in treated participants and 21 in total in non-
treated participants), it is important to note that only three trials
defined adverse events, one with a detailed definition of qualifying
adverse events (Kelly 1996 ZMB), and two with more general-
ized definitions (Suputtamongkol 2011 THA;Webb 2012 UGA).
Only one trial reported how adverse events were monitored, using
patient record-keeping cards and house visits (Kelly 1996 ZMB).
Despite these biases, most randomized controlled trials (RCTs)
reported no adverse events following antihelminthic therapy and
there is no evidence of excessive harm associated with deworming
in HIV-positive populations. To validate review findings, larger
RCTs should be conducted with well-documented and active ad-
verse event identification, as well as frequent follow-up points to
assess how deworming may affect HIV-positive populations of all
ages over time.
Quality of the evidence
We have presented the GRADE assessment of the quality of ev-
idence in the included trials in the ’Summary of findings’ ta-
bles (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3). The overall assessment of
quality ranges from moderate (representing a moderate level of
certainty in the result) to very low (where we are very uncertain of
the result).
The primary reason for downgrading the quality of evidence was
’indirectness’, where we had too few trials to make broad gener-
alizations about the potential effects. This is a particular problem
for trials that evaluate deworming in populations with unknown
helminth infection status as helminth endemicity varies substan-
tially across settings, undoubtedly influencing observed findings.
Although we had more data from trials that evaluated deworm-
ing drugs in participants with documented helminth infections,
the substantial heterogeneity in populations and deworming drugs
used again decreased our confidence in making broad generaliza-
tions. The secondmost common reason for downgrading the qual-
ity of evidence was ’imprecision’ in effect estimates. Many of the
included trials were small, and had wide 95%CIs, which included
the possibility of both clinically important effects and no effect.
Potential biases in the review process
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Judd Walson is a co-author of this Cochrane Review and was
Primary Investigator on two of the included RCTs. However, he
was not involved in conducting any of the ’Risk of bias’ assessments
or in data extraction for this Cochrane Review.
There were not enough trials available in the published literature
to be able to assess for publication bias.
Agreements and disagreements with other
studies or reviews
The first review on this topic, Walson 2007a, identified only one
RCT for inclusion that evaluated the potential benefit of treating
helminth co-infection in HIV-1-infected individuals (Kallestrup
2005 ZWE). Subsequently two additional RCTs were published
(Nielsen 2007 TZA;Walson 2008 KEN), and a Cochrane Review
of all three RCTs concluded that treatment of helminth co-infec-
tion appeared to result in favourable effects on markers of HIV-1
disease progression (Walson 2009). Specifically, the pooled analy-
sis of the data suggested that treatment of helminth co-infection
may attenuate increases in HIV-1 RNA and result in slower de-
cline in CD4+ counts.
The findings of this Cochrane Review update are consistent
with the previous edition (Walson 2009). However, we used the
GRADE approach to assess the quality of evidence, which caused
us to downgrade the quality of the evidence. As we stratified by
helminth infection status, we also separately provide evidence for
individuals who were helminth-infected or of unknown infection
status.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is low quality evidence that treating confirmed helminth in-
fections in HIV-positive adults has a short-term favourable effect
on markers of HIV disease progression. Further studies are nec-
essary to confirm this finding. However, there is no evidence that
deworming is harmful. This is reassuring for the routine treatment
of confirmed or suspected helminth infections in people living
with HIV in co-endemic areas.
Further long-term studies would be required to make conclusions
about the likely impact of a policy of deworming all HIV-positive
individuals irrespective of helminth infection status (i.e. preventive
chemotherapy) as the only trial to date did not demonstrate an
effect.
Given the large favourable effect of ART on HIV disease progres-
sion, the additive effect of regular deworming, if any, is unknown.
Implications for research
Further long-term studies are required to make conclusions re-
garding the likely impact of deworming all HIV-positive individ-
uals irrespective of helminth infection status, as the only trial to
date did not demonstrate an effect.
Future RCTs should consider measuring both helminth infection
status and long-termHIVdisease progression outcomes repeatedly
between baseline and end line to understand how disease progres-
sion changes over differential amounts of follow-up time. These
RCTs should have well-documented and active adverse event iden-
tification. Given that deworming is often targeted at preschool
and school-age children, it is also important to identify the benefit
in HIV-positive children.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abate 2014 ETH
Methods Trial design: randomized, double-blind, placebo-controlled trial
Participants: adults with and without HIV infection who were found to be co-infected
with soil-transmitted helminths (STHs) and tuberculosis (TB).Data of theHIV seropos-
itive cohort only are included in this analysis
Length of follow-up: relevant outcomes (CD4+ T cell count) were recorded at baseline
and after three months.
Monitoring and diagnostics: all helminth co-infections were diagnosed using triplicate
stool samples, direct microscopy, and Kato-Katz techniques. Participants were routinely
tested for human immunodeficiency virus (HIV) at TB treatment centres using rapid
test kits, Stat-Pak, and Unigold
Participants Number of participants: a total of 140 helminth-positive TB participants were enrolled
and randomized. 72 participants were randomized to the treatment arm and 68 to
the placebo arm. We included only data from the 18 HIV-positive participants in the
treatment arm and 14 HIV-positive participants in the placebo arm in this Cochrane
Review.
Inclusion criteria: newly diagnosed TB participants (15 to 60 years of age) presenting at
a university referral hospital and co-infected with an STH infection
Exclusion criteria: participants that required hospital admission, were pregnant, infected
with Schistosoma spp., displayed symptoms of active helminth infection, or displayed
signs of any concomitant chronic or infectious disease other than TB/HIV
Interventions Intervention: albendazole treatment (400 mg/day) for 3 consecutive days. All helminth-
positive TB participants, including the placebo group, received deworming treatment at
week 12. Randomization occurred 2 weeks following TB treatment
Control: identical placebo tablets.
Outcomes Outcomes included in this review: change in CD4+ T cells after three months, adverse
events, and mortality events
Other trial outcomes: the primary outcome of the trial was change in TB score after
2 months. Other secondary outcomes were sputum smear conversion after 2 months,
changes in the chest x-ray pattern at week 12, IgE and eosinophil responses, as well
as changes in the frequency of Tregs and IFN-c, IL-5, and IL-10 producing peripheral
blood mononuclear cells (PBMCs) after 3 months
Notes Location: Gondar, Ethiopia.
Participant helminth status: ascertained.
Participant antiretroviral (ART) status: 94% and 100% of participants were on ART in
the intervention and placebo groups, respectively
Note: this is the only trial in which all participants had a major co-infection beyond the
helminth and HIV relationship of interest, which might limit comparability to other
findings in this review
Author contact: we requested additional data for the HIV cohort alone from the trial
authors, who provided the data
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Abate 2014 ETH (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random numbers were generated in a
block size of eight by the Addis Continen-
tal Institute of Public Health, Ethiopia.”
Allocation concealment (selection bias) Low risk “All tablets looked identical and were as-
signed a treatment code by the manufac-
turer.The treatment allocated for each pa-
tient was concealed in an individual enve-
lope.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both the investigators and clinic staff were
blinded to the treatment given.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The treatment code was kept in a sealed
envelope at the manufacturer and opened
after the last patient had been to a follow-
up visit and the data had been analysed.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No risk of attrition; 15% lost to follow-
up with 72 participants in the intervention
group and 68 participants in the control
group
Kallestrup 2005 ZWE
Methods Trial design: randomized, unblinded, controlled trial.
Participants: adults with and without HIV-1 infection who were found to be infected
with schistosomes. We only included data from the HIV seropositive cohort in this
analysis
Length of follow-up: HIV-1 RNA and CD4+ T cell counts were measured at baseline
and after 3 months
Monitoring and diagnostics: from Kallestrup 2005; Status for HIV was determined by a
rapid HIV-1/2 test in the field on a dry blood spot and two enzyme-linked immunosor-
bent assays on serum. Infection with Schistosoma haematobium was diagnosed by micro-
scopic identification and quantification of fixed-volume urine samples filtered on Nytrel
filters. Diagnosis of infection with Schistosoma mansoni and other helminth eggs or par-
asites was assessed by the modified formol-ether concentration technique on 1 g of stool
from each participant
Participants Number of participants: 287 individuals were enrolled of whom we included 130 with
HIV-1 and schistosome co-infection in this analysis. 64 participants received early praz-
iquantel treatment and 66 received delayed treatment
Inclusion criteria:HIV-1 and schistosomiasis co-infection,HIV-negative schistosomiasis
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Kallestrup 2005 ZWE (Continued)
infected, HIV-1 negative but schistosomiasis infected, or neither infection
Exclusion criteria: pregnant women and participants presentingwith clinical signs/symp-
toms of TB, terminal stages of schistosomiasis, or severe anaemia
Interventions Intervention: participants received a single oral dose of praziquantel (40 mg/kg) at en-
rolment or after a delay of 3 months
Control: participants received a single oral dose of praziquantel (40 mg/kg) after a delay
of 3 months following enrolment
Outcomes Outcomes included in this review: changes in plasma HIV-1 RNA levels, CD4+ T cell
count, and haemoglobin levels between individuals randomized to early versus delayed
treatment
Other trial outcomes: none
Notes Location: Shamva District, Zimbabwe.
Participant helminth status: ascertained.
Participant ART status: not stated.
Author contact: we requested additional haemoglobin data from the trial authors for this
update, who provided the data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Exact random sequence generation used
unclear. FromKallestrup 2005: “Allocation
of participants to these 3 control groupswas
done randomly: 1 participant with schisto-
somiasis was selected for every 2 coinfected
participants, and 1 HIV-1-positive partic-
ipant or 1 healthy participant was selected
for every 4 coinfected participants.”
Allocation concealment (selection bias) High risk Allocation concealment was not done. “On
inclusion, all participants infected with
schistosomes within each HIV-1 group
were openly randomised”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded; “On inclusion, all partici-
pants infected with schistosomes within
eachHIV-1 groupwere openly randomised
into 2 equally sized groups”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk From Kallestrup 2005: “At all stages, when
performing parasitological examinations,
the technician was blinded to clinical and
serological information”
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Kallestrup 2005 ZWE (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk There is a risk of attrition as there was <
80% follow-up.
Kelly 1996 ZMB
Methods Trial design: randomized double blind placebo controlled trial
Participants: HIV-1 or HIV-2 seropositive adults with persistent diarrhoea
Length of follow-up: adverse andmortality events were recorded over 6months of follow-
up
Monitoring and diagnostics: ELISA tests were used to determine HIV seropositivity.
Home care staff noted any potential adverse effects
Participants Number of participants: 174 participants were initially randomized but only 138 par-
ticipants were followed-up after 1 month and considered correctly randomized, with 69
in the intervention group and 69 in the placebo-controlled group
Inclusion criteria: HIV-positive adults with persistent diarrhoea (defined as loose but
not bloody stools 3 or more times a day for 3 weeks or longer)
Exclusion criteria: participants were excluded if they had received antibiotics in the
preceding week, or were deteriorating clinically (Karnofsky score ≤ 20)
Interventions Intervention: 800 mg albendazole twice daily for 14 days for treatment of persistent
diarrhoea in HIV-positive participants
Control: identical placebos twice daily for 14 days.
Outcomes Outcomes included in this review: incidence of adverse events andmortality. Incidence of
adverse events defined as exacerbated diarrhoea, cutaneous reaction, dizziness, headache,
cough, and difficulty swallowing
Other trial outcomes: proportionof time periods duringwhich diarrhoeawas experienced
after completion of treatment and proportion of participants with full remission after
completion of treatment
Notes Location: 3 urban hospitals/health centres in Zambia.
Participant helminth status: not ascertained.
Participant ART status: not specified, but the study took place before treatment was
widely available in Zambia
Author contact: we did not contact the trial authors to provide additional information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “the patients were randomised by alloca-
tion of a study pack containing either al-
bendazole or placebo, which had been pre-
pared in London according to a randomi-
sation code.”
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Kelly 1996 ZMB (Continued)
Allocation concealment (selection bias) Low risk “The code (constructed so that the num-
bers of patients randomised to albendazole
and placebo balanced every 20 patients)
was kept in London during the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Each pack contained 112 tablets of al-
bendazole or placebo, which were indistin-
guishable.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear whether or not the assessor was
blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk There is a risk of attrition as there was <
80% follow-up.
Nielsen 2007 TZA
Methods Trial design: randomized double-blind placebo-controlled cross-over trial
Participants: HIV-positive individuals with or withoutWuchereria bancrofti co-infection.
Length of follow-up: all subjects were followed-up at 1, 12, 13, and 24 weeks after the
1st round of treatment. The data presented in the published manuscript considered the
12-week visit as the initial visit and the 24-week visit as the final visit. Individuals treated
at the initial visit with diethylcarbamazine (DEC) were then considered as the ’placebo’
arm and those who were not treated until the 12-week visit were the ’treatment’ arm.
For the purposes of this analysis, we considered only individuals with confirmed HIV-1
infection who were also filariasis-infected at the baseline visit. We considered individuals
treated with DEC at the initial visit to be in the ’treatment’ arm and those who did not
receive treatment to be in the ’placebo’ arm. We reported outcomes as indicated for the
12-week visit. As all participants were treated with DEC by the 12 week visit, we did
not include data from the 24-week follow-up period
Monitoring anddiagnostics: diagnosis of infectionwith lymphatic filariasis (LF) infection
with W. bancrofti was performed using immunochromatographic tests (ICT) followed
by ELISA testing for circulating filarial antigens (CFA) in serum samples. Participants
were also screened for malaria and intestinal helminth eggs
Participants Number of participants: the trial authors screened 858 adults and 34 HIV-1 infected
individuals were enrolled and randomized in the trial, of which 27 were followed-up.
Eighteen were co-infected with W. bancrofti, and 16 were not co-infected. In the co-
infected group, 10 participants were randomized to early treatment and 8 participants
were randomized to delayed treatment. Twelve of these participants were followed-up,
6 in each treatment group. The HIV RNA from one of the participants in the delayed
treatment arm could not be amplified
Inclusion criteria: HIV-positive individuals without clinical manifestations of HIV, with
and without LF infection
Exclusion criteria: none specified.
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Nielsen 2007 TZA (Continued)
Interventions Intervention: DEC (6 mg/kg) at randomization.
Control: equivalent placebo and treatment after a delay of 3 months
Outcomes Outcomes included in this review: plasma HIV-1 RNA levels, CD4+ cell count, CD4
percent, serum concentrations of ferritin, adverse events
Other trial outcomes: CD4/CD8 ratio between individuals randomized to early versus
delayed treatment (3 months later) (Nielsen 2007 TZA). Baseline and change in serum
retinol, β-carotene, α-tocopherol, and the acute phase reactant a-1 antichymotrypsin
after 3 months (Nielsen 2009)
Notes Location: Northeastern Tanzania
Participant helminth status: ascertained
Participation ART status: the trial authors did not specify if any participants were re-
ceiving ART treatment at the start or during the trial
Author contact: we requested additional CD4 and HIV-1 RNA data from the trial
authors, who provided the data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Individuals were randomised (1:1). “The
identical DEC and placebo tablets were
packed in containers with different color
codes (“red” or “blue”). Individuals were
randomised (1:1) to receive treatment in
the order of “red” followed by “blue” or
“blue” followed by “red” by using a list of
random numbers.The selected study par-
ticipants were listed and numbered from 1
to 34, and the first 17 numbers (between
1 and 34) encountered in the table (when
starting on a randomly chosen figure) were
assigned to receive treatment in the order
red-blue, and the remaining 17 received
treatment in the order blue-red.”
Allocation concealment (selection bias) Unclear risk This was not specified.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All study personnel and participants were
blinded to treatment assignment through-
out the study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear whether or not the assessor was
blinded.
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Nielsen 2007 TZA (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk There is a risk of attrition as there was <
80% follow-up. However, this reflects 7
participants whowere lost to follow-up and
therefore excluded from the analyses. The
excluded participants did not significantly
differ at baseline from the included partic-
ipants
Suputtamongkol 2011 THA
Methods Trial design: randomized, non-blinded study.
Participants: adult participants with chronic strongyloidiasis
Length of follow-up: participants were followed up 2 weeks after treatment initiation,
then 1 month, 3 months, 6 months, 9 months, and 1 year post-treatment
Monitoring and diagnostics: infection with Strongyloides stercoralis was ascertained using
the direct smear, formol-ether concentration method, and modified Koga agar plate
culture method
Participants Number of participants: 90 adult participants with chronic Strongyloides infection were
recruited. There were 10 participants with HIV co-infections, with 3 HIV-positive par-
ticipants randomized to albendazole, 2 HIV-positive participants randomized to single
dose ivermectin, and 5 HIV-positive participants randomized to double dose ivermectin
Inclusion criteria: adult participantswith characteristic rhabditiform larvae of S. stercoralis
present on faecal microscopy.
Exclusion criteria: history of allergic reaction to either studymedication, treatmentwithin
the month prior to the trial with any drug known to have anti-Strongyloides activity,
pregnancy, or lactation, and any suggestion of disseminated strongyloidiasis
Interventions Intervention: Group 1: ivermectin delivered as a single dose of 200 µg/kg; Intervention.
Group 2: 2 doses of ivermectin (200 µg/kg) delivered 2 weeks apart. For the purpose of
this analysis we considered both groups that received ivermectin together
Control: participants received 7 days of albendazole (800 mg per day)
Outcomes Outcomes included in this review: incidence of adverse events defined as “symptoms or
signs that developed after the study drug administration and had not been reported prior
to the administration of the first dose of the antihelmintic.”
Other trial outcomes: treatment cure (defined as clinical improvement (if symptomatic
before treatment) and the absence of rhabditiform larvae in the stool at day 14 of treat-
ment and throughout the follow-up period) and treatment failure (defined as the pres-
ence of larvae two weeks after initiation of treatment or the reappearance of larvae during
follow-up)
Notes Location: Siriraj Hospital, Thailand
Participant helminth status: ascertained
ParticipantARTstatus: it was unspecified if any individualswere receivingART treatment
at the start or during the trial
Author contact: we requested additional data regarding the incidence of adverse events
in the HIV-positive participants specifically from the trial authors, who provided this
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Suputtamongkol 2011 THA (Continued)
information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer generated, simple, random al-
location sequences were prepared for 3
study groups by the investigator team.”
Allocation concealment (selection bias) Low risk “These were sealed in an opaque envelope
and numbered. The investigator assigned
study participants to their respective treat-
ment group after opening the sealed enve-
lope.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “prospective open-label, randomised, con-
trolled study”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear whether or not the assessor was
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was 10% loss to follow-up; “Ten pa-
tients were excluded from analysis because
they did not receive or complete the study
treatment (3 in albendazole group, 2 in
ivermectin-II group), or they were lost to
follow-up immediately after treatment (3
in albendazole group, 1 each in ivermectin-
I and ivermectin-II respectively).”
Walson 2008 KEN
Methods Trial design: randomized double-blind placebo-controlled trial
Partcipants: HIV-1 positive adults with evidence of co-infection with albendazole-treat-
able STHs
Length of follow-up: all subjects were followed-up at 12 weeks post-randomization
Monitoring and diagnostics: helminth diagnosis was performed using stool samples pro-
cessed and evaluated with wet preparation, Kato-Katz, and formol-ether concentration
techniques. HIV-1 was diagnosed using Determine™ rapid test qualitative immunoas-
say. The CD4 lymphocyte count was determined using Multiset™ software on a FAC-
SCalibur machine. PlasmaHIV-1 RNAwas quantified using the Gen-ProbeHIV-1 viral
load assay
Participants Number of participants: the trial screened 1551 adults attending HIV care clinics and
299 were infected with at least 1 helminth species. Regarding enrolment, 234 ART-
naive individuals were enrolled, of whom 208 HIV and STH co-infected (hookworm,
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Walson 2008 KEN (Continued)
Ascaris, Trichuris, or Strongyloides) individuals were included in the final analysis, 108
were randomized to receive early treatment and 100 to receive placebo
Inclusion criteria: HIV-1 seropositive adults, not pregnant, and ineligible for initiation
of ART based on WHO guidelines (CD4 < 200 cells/mm³, any stage 4 and some stage
3 disease)
Exclusion criteria: ever used ART drugs, took medicine for helminth infection in the
preceding 6 months, evidence of active TB or TB treatment in the past 3 months, and
clinical signs of severe anaemia
Interventions Intervention: albendazole (400 mg per day) for 3 days versus placebo at enrolment
Control: placebo at enrolment. After a delay of 3 months, all participants showing
evidence of helminth infectionwere treatedwith albendazole, regardless of randomization
arm
Outcomes Outcomes included in this review: changes in plasma HIV-1 RNA levels and CD4+
count between individuals randomized to early versus delayed treatment (3months later)
and adverse events
Other trial outcomes: none.
Notes Location: 10 sites throughout Kenya.
Participant helminth status: ascertained.
Participant ART status: treatment naive.
Author contact: the trial author provided additional CD4 and HIV-1 RNA data for
inclusion in this Cochrane Review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were randomly assigned to
two groups using a 1:1 allocation scheme
with block randomisation of 30 patients
and following a random-allocation list gen-
erated independently.”
Allocation concealment (selection bias) Low risk “Pre-labeled, sequentially numbered treat-
ment packs were used. Both the active drug
(albendazole) and an identical appearing
placebo were provided by the drug manu-
facturer.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Investigators, clinic staff and patients were
blinded to study-group assignment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear whether or not the assessor was
blinded.
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Walson 2008 KEN (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No risk of attrition; 0.5% lost to follow-
up, with 4 in the intervention arm and 5 in
the control arm
Walson 2012 KEN
Methods Trial design: non-blinded randomized study.
Partcipants: HIV-positive ART naive adults in Kenya.
Length of follow-up: CD4+ cell counts measured every 6 months and plasma RNA
measured every 12 months. Participants were followed for 24 months
Monitoring and diagnostics: HIV serological testing was conducted with Determine™
rapid tests, CD4 cell counts using a FACSCalibur™, plasma HIV RNA assays with the
COBAS® Amplicor assay
Participants Number of participants: 979 individuals were screened for enrolment in the trial and 917
individuals were enrolled and eligible, with 449 participants randomized to the treatment
group and 468 randomized to the control group. All participants were administered
cotrimoxazole prophylaxis
Inclusion criteria: adults≥ 18 years, HIV seropositive, and do not meet criteria for ART
initiation (on the basis of documented WHO disease stage and CD4+ cell count within
the previous 3 months and a clinical assessment at enrolment)
Exclusion criteria: pregnancy, reports of taking antihelminthics in the previous 6months,
reports of having previously received ART ((except for the prevention of mother-to-child
transmission)
Interventions Intervention: empiric deworming with repeat single-dose albendazole (400 mg) given
every 3 months plus single dose praziquantel (25 mg/kg) given annually. Participants
were excluded if they missed two or more consecutive doses of study drug
Control: standard of care.
Outcomes Outcomes included in this review: changes in plasma HIV-1 RNA levels, CD4+ cell
count, non-traumatic death, and adverse events between individuals randomized to
treatment versus no intervention
Other trial outcomes: time to CD4+ count of < 350 cells/µL and first occurrence of
any of the following: CD4+ count < 350 cells/µL, first reported use of ART (excluding
that used for the prevention of mother-to-child transmission), or non-traumatic death.
Secondary analyses included time to death and ART initiation separately
Notes Location: 3 sites in Kenya
Participant helminth status: helminth status of participants was not evaluated at baseline
Participant ART status: treatment naive
Author contact: the trial author provided additional CD4+ and HIV-1 RNA data for
inclusion in this Cochrane Review
Risk of bias
Bias Authors’ judgement Support for judgement
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Walson 2012 KEN (Continued)
Random sequence generation (selection
bias)
Low risk “Using a computer-generated randomisa-
tion sequence, we assigned participants (1:
1) to either the treatment group or control
group.”
Allocation concealment (selection bias) Low risk “We used a computerised database to en-
sure that treatment allocation was not dis-
closed to study staff and participants until
randomisation was complete.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The trial participants and personnel were
not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear whether or not the assessor was
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There is no risk of attrition; 4.2% of par-
ticipants were lost to follow-up with 16 in
the intervention arm and 24 in the control
arm
Webb 2012 UGA
Methods Trial design: 2 x 2 randomized double-blind placebo controlled trial
Partcipants: HIV-positive ART-naive pregnant women.
Length of follow-up: viral load was measured 6 weeks post-treatment and at delivery.
However, this analysis included data at 6 weeks post-treatment only in order to minimize
the effects of prenatal HIV care provided to study participants
Monitoring and diagnostics: stool samples were processed and examined for helminth
ova using a duplicate Kato-Katz method and by charcoal culture for Strongyloides.
Participants Number of participants: 2507 women were enrolled in the parent study (EMaBS), of
whom 299 tested positive for HIV. Of these, 222 participants were randomized and fol-
lowed-up to 6 weeks post-enrolment. Sixty-four participants were randomized to single-
dose albendazole, 54 participants to praziquantel, 67 participants to both albendazole
and praziquantel, and 70 participants to placebo only
Inclusion criteria: pregnant women presenting at the government-funded antenatal clinic
at Entebbe General Hospital, who were resident in the study area, planning to deliver
in the hospital, willing to know their HIV status, and in the 2nd or 3rd trimester of
pregnancy
Exclusion criteria: evidence of possible helminth-induced pathology (haemoglobin < 8
g/dL, clinically apparent severe liver disease, diarrhoea with blood in stool), history of
adverse reaction to antihelminthics, prior enrolment in an earlier pregnancy, or abnormal
pregnancy as assessed by the midwife
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Webb 2012 UGA (Continued)
Interventions Intervention 1: albendazole (400 mg).
Intervention 2: praziquantel (40 mg/kg).
Intervention 3: both albendazole (400 mg) and praziquantel (40 mg/kg)
Control: equivalent placebos.
Outcomes Outcomes included in this review: changes in plasma HIV-1 RNA levels 6 weeks post-
treatment, adverse events (defined as post-treatment hospitalizations), and mortality
Other trial outcomes: primary outcomes for EMaBS were response to immunisation and
incidence of infectious diseases in the offspring, and vertical transmission of HIV (Webb
2011). Secondary outcomes in this analysis included viral load at delivery
Notes Location: Entebbe, Uganda.
Participant helminth status: ascertained.
Participant ART status: ART naive. However, in accordance with guidelines at the time,
HIV-positive women were counselled and given intrapartum and neonatal single dose
nevirapine for preventionofmother-to-childHIV transmission. After enrolment, women
received standard antenatal care, including haematinics, tetanus immunization, and in-
termittent presumptive treatment for malaria
Author contact: we requested additional HIV-1 RNA and adverse events data from the
trial authors, who provided this information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Women were then randomised in a 1:1:1:
1 ratio to single-dose albendazole 400 mg
or matching placebo and praziquantel 40
mg/kg or matching placebo in a 2×2 fac-
torial design. The randomisation code was
generated by the trial statistician in blocks
of 100.”
Allocation concealment (selection bias) Low risk “Sealed envelopes containing the study in-
tervention were prepared by colleagues at
the Medical Research Council Unit in En-
tebbe with no other involvement in the
trial. Treatments were allocated in numeri-
cal order by trained interviewer-counsellors
and taken under observation.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All participants and staff were blinded to
treatment allocation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear whether or not the assessor was
blinded.
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Webb 2012 UGA (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk There is no risk of attrition; 10% of partic-
ipants were lost to follow-up
Abbreviations: antiretroviral treatment (ART), circulating filarial antigens (CFA), diethylcarbamazine (DEC), human immunodefi-
ciency virus (HIV), immunochromatographic tests (ICT), soil-transmitted helminths (STHs), tuberculosis (TB)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Blish 2010 This manuscript presents further analyses using data already presented in Walson 2008 KEN
Brown 2004 Observational, prospective cohort study.
Brown 2005 Observational, prospective cohort study.
Elliott 2003 Observational, prospective cohort study.
Elliott 2007 Study protocol for included study Webb 2012 UGA.
Erikstrup 2008 This manuscript presents further analyses using data already presented in Kallestrup 2005 ZWE.
Esan 2013 A RCT with non-relevant intervention (that is, iron supplementation and multivitamins) to assess effects of
anaemia in children 6 to 59 months of age
Finkelstein 2012 Observational, prospective cohort study.
Fischer 1995 Observational, prospective cohort study.
Gallagher 2005 Observational, retrospective cohort study.
Ganley-Leal 2006 Observational, prospective cohort study.
Geelhoed 2006 Observational, prospective case-control study, with irrelevant outcomes to this Cochrane Review
Heath 1996 Case study of a single participant.
Hosseinipour 2007 Observational, cross-sectional study.
Ivan 2015 Observational, cross-sectional study.
Joseph 2004 Observational, prospective cohort study.
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(Continued)
Kallestrup 2006 This manuscript presents further analyses using data already presented in Kallestrup 2005 ZWE.
Karanja 1998 Observational, prospective cohort study.
Kassu 2003 Observational, prospective cohort study.
Kipp 2005 Observational, prospective cohort study.
Kleppa 2014 Observational, case-control study.
Lankowski 2014 Observational retrospective cohort study.
Lawn 2000 Observational, prospective cohort study with no comparison group
McElroy 2005 Observational, cross-sectional study.
Modjarrad 2005 Observational, prospective cohort study.
Mulu 2013 Observational, prospective cohort study.
Muok 2013 Observational, prospective cohort study
Mwanakasale 2003 Observational, prospective cohort study.
Ndibazza 2012 A RCT with irrelevant outcomes to this Cochrane Review. The study authors hypothesize that antihelminthic
treatment in pregnancy and early childhood would improve responses to immunization and modulate disease
incidence in early childhood
Watanabe 2007 Observational, prospective cohort study.
Wolday 2002 Observational, prospective cohort study.
Zinyama 2009 Observational, prospective cohort study.
Zulu 2002 Observational, prospective cohort study.
Abbreviations: RCT: randomized controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Deworming drugs versus placebo in people with unknown helminth infection status
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Viral load: change in log10 HIV-
1 RNA
2 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 At 6 weeks after one dose 1 166 Mean Difference (IV, Random, 95% CI) -0.14 [-0.35, 0.07]
1.2 At 2 years after multiple
doses
1 917 Mean Difference (IV, Random, 95% CI) 0.01 [-0.03, 0.05]
2 Change in CD4 count 1 917 Mean Difference (IV, Random, 95% CI) 2.60 [-10.15, 15.35]
2.1 At 2 years after multiple
doses
1 917 Mean Difference (IV, Random, 95% CI) 2.60 [-10.15, 15.35]
Comparison 2. Deworming drugs versus placebo in people with confirmed helminth infection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Viral load: change in log10 HIV-
1 RNA
4 445 Mean Difference (IV, Random, 95% CI) -0.13 [-0.26, -0.00]
1.1 Soil-transmitted
helminths
2 273 Mean Difference (IV, Random, 95% CI) -0.10 [-0.31, 0.12]
1.2 Schistosomiasis 2 161 Mean Difference (IV, Random, 95% CI) -0.13 [-0.36, 0.10]
1.3 Lymphatic filariasis 1 11 Mean Difference (IV, Random, 95% CI) -0.08 [-0.93, 0.77]
2 Change in CD4 count 3 358 Mean Difference (IV, Random, 95% CI) 37.86 [7.36, 68.35]
2.1 Soil-transmitted
helminths
2 228 Mean Difference (IV, Random, 95% CI) 40.69 [1.51, 79.87]
2.2 Schistosomiasis 1 130 Mean Difference (IV, Random, 95% CI) 33.5 [-15.06, 82.06]
Comparison 3. Deworming drugs versus placebo; all trials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in log10 HIV RNA, by
antihelminthic
5 1534 Mean Difference (IV, Random, 95% CI) -0.09 [-0.19, 0.01]
1.1 Albendazole 2 302 Mean Difference (IV, Random, 95% CI) -0.18 [-0.37, 0.02]
1.2 Praziquantel 2 213 Mean Difference (IV, Random, 95% CI) -0.17 [-0.32, -0.03]
1.3 Diethylcarbamazine 1 11 Mean Difference (IV, Random, 95% CI) -0.08 [-0.93, 0.77]
1.4 Albendazole and
praziquantel
2 1008 Mean Difference (IV, Random, 95% CI) 0.01 [-0.04, 0.05]
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2 Difference in adverse events
between treatment and no
treatment groups
7 1649 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.53, 2.83]
3 Difference in mortality events
between treatment and no
treatment groups
5 1627 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.52, 1.14]
A D D I T I O N A L T A B L E S
Table 1. Cochrane librarian search strategy for MEDLINE
Number Search terms
#1 Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR
hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR
human immuno-deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*[tiab]) AND
(deficiency virus[tiab])) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab]
OR acquired immuno-deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired im-
mun*[tiab]) AND (deficiency syndrome[tiab])) OR “sexually transmitted diseases, Viral”[MeSH:NoExp]))
#2 Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR
drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])
#3 Search (helminths[mh] OR helminth*[tiab] OR nematode*[tiab] OR worm*[tiab] OR parasites[mh] OR parasit*[tiab]
OR round worm*[tiab] OR roundworm*[tiab] OR hookworm*[tiab] OR hook worm*[tiab] OR ancylostoma*[tiab] OR
cestode*[tiab]OR tapeworm*[tiab]OR tape worm*[tiab]OR trematode*[tiab]ORfluke*[tiab]ORwhipworm*[tiab]OR
whip worm*[tiab] OR trichuris[tiab] OR ascaris[tiab] OR enterobi*[tiab] OR strongyloide*[tiab] OR mansonell*[tiab]
OR taenia[tiab] schistosom*[tiab] OR necator*[tiab] OR paragonim*[tiab] OR hymenolepis[tiab] OR fasciol*[tiab] OR
filariasis[tiab] OR trichostrongl*[tiab] ORmicrofilaria[tiab] OR parasitic diseases[mh:noexp] OR helminthiasis[mh] OR
intestinal diseases, parasitic[mh])
#4 Search (benzimidazoles OR albendazole OR mebendazole OR ivermectin OR praziquantel OR diethylcarbamazine OR
bithionol OR oxamniquine OR pyrantel OR nitazoxanide OR anthelmintic OR anthelmintics OR anthelminthic OR
anthelminthicsOR “anti helminthic”OR “anti helminthics”OR “anti helmintic”OR “anti helmintics”OR antihelminthic
OR antihelminthics OR antihelmintic OR antihelmintics)
#5 Search (#1 AND #2 AND #3 AND #4)
#6 Search (((#1 AND#2 AND#3 AND#4))) AND (“1980/01/01”[Date - Publication] : “2015/09/29”[Date - Publication])
Table 2. Cochrane librarian search strategy for EMBASE
Number Search terms
#1 ’human immunodeficiency virus infection’ expOR ’human immunodeficiency virus infection’:ab,ti OR ’hiv infection’:ab,
ti OR ’hiv infections’:ab,ti OR ’human immunodeficiency virus’/exp OR ’human immunodeficiency virus’:ab,ti OR hiv:
ab,ti OR ’hiv 1’:ab,ti OR ’hiv 2’:ab,ti OR ’human immune deficiency virus’:ab,ti OR ’human immuno deficiency virus’:
ab,ti OR ’acquired immunodeficiency syndrome’:ab,ti OR ’acquired immuno deficiency syndrome’:ab,ti OR ’acquired
immune deficiency syndrome’:ab,ti OR ’acquired immunedeficiency syndrome’:ab,ti
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Table 2. Cochrane librarian search strategy for EMBASE (Continued)
#2 ’randomized controlled trial’/de OR ’randomized controlled trial’ OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR
factorial*:ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volunteer*:ab,ti OR ’crossover procedure’/de OR ’crossover pro-
cedure’OR ’double-blind procedure’/de OR ’double-blind procedure’ OR ’single-blind procedure’/de OR ’single-blind
procedure’ OR (doubl*NEAR/3 blind*):ab,ti OR (singl*:ab,ti AND blind*:ab,ti) OR crossover*:ab,ti OR cross+over*:
ab,ti OR (crossNEXT/1 over*):ab,ti
#3 ’animal’/de OR ’animal experiment’/de OR ’invertebrate’/de OR ’animal tissue’/de OR ’animal cell’/deOR ’nonhuman’/
de
#4 ’human’/de OR ’normal human’/de OR ’human cell’/de
#5 #3 AND #4
#6 #3 NOT #5
#7 #2 NOT #6
#8 ’helminth’/exp OR helminth*:ab,ti OR nematode*:ab,ti OR worm*:ab,ti OR ’parasite’/exp OR parasit*:ab,ti OR roun-
dANDworm*:ab,ti OR roundworm*:ab,ti OR hookworm*:ab,ti OR hookANDworm*:ab,ti OR ancylostoma*:ab,ti OR
cestode*:ab,ti OR tapeworm*:ab,ti OR tapeANDworm*:ab,ti OR trematode*:ab,ti OR fluke*:ab,ti ORwhipworm*:ab,ti
ORwhipANDworm*:ab,tiOR trichuris:ab,tiOR ascaris:ab,tiOR enterobi*:ab,tiOR strongyloide*:ab,tiORmansonell*:
ab,ti OR taenia:ab,ti AND schistosom*:ab,ti OR necator*:ab,ti OR paragonim*:ab,ti OR hymenolepis:ab,ti OR fasciol*:
ab,ti OR filariasis:ab,ti OR trichostrongl*:ab,ti OR microfilaria:ab,ti OR ’parasitic diseases’/exp OR ’helminthiasis’/de
OR ’intestine infection’/de
#9 ’benzimidazoles’/de OR benzimidazolesOR ’albendazole’/de OR albendazoleOR ’mebendazole’/de OR mebendazoleOR
’ivermectin’/de OR ivermectinOR ’praziquantel’/de OR praziquantelOR ’diethylcarbamazine’/de OR diethylcarbamazi-
neOR ’bithionol’/de OR bithionolOR ’oxamniquine’/de OR oxamniquineOR ’pyrantel’/de OR pyrantelOR ’nitazox-
anide’/de OR nitazoxanideOR ’anthelmintic’/de OR anthelminticOR ’anthelmintics’/de OR anthelminticsOR ’an-
thelminthic’/de OR anthelminthicOR anthelminthicsOR ’anti helminthic’OR ’anti helminthics’OR ’anti helmintic’OR
’anti helmintics’OR antihelminthicOR antihelminthicsOR ’antihelmintic’/de OR antihelminticOR ’antihelmintics’/de
OR antihelmintics
#10 #1 AND #7 AND #8 AND #9
#11 #1 AND #7 AND #8 AND #9 AND [1-1-1980]/sd NOT [29-09-2015]/sd
Table 3. Cochrane librarian search strategy for CENTRAL
Number Search terms
#1 MeSH descriptor: [HIV Infections] explode all trees
#2 MeSH descriptor: [HIV] explode all trees
#3 hiv or hiv-1* or hiv-2* or hiv1 or hiv2 or (hiv near infect*) or (human immunodeficiency virus) or (human immunedefi-
ciency virus) or (human immune-deficiency virus) or (human immuno-deficiency virus) or (human immune deficiency
virus) or (human immuno deficiency virus) or (acquired immunodeficiency syndrome) or (acquired immunedeficiency
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Table 3. Cochrane librarian search strategy for CENTRAL (Continued)
syndrome) or (acquired immuno-deficiency syndrome) or (acquired immune-deficiency syndrome) or (acquired immun*
deficiency syndrome) (Word variations have been searched)
#4 MeSH descriptor: [Lymphoma, AIDS-Related] this term only
#5 MeSH descriptor: [Sexually Transmitted Diseases, Viral] this term only
#6 #1 or #2 or #3 or #4 or #5
#7 [mh helminths] or helminth*:ti,ab,kw or meatode*:ti,ab,kw or worm*:ti,ab,kw or [mh parasites] or parasit*:ti,ab,kw or
roundworm:ti,ab,kwor roundworm:ti,ab,kwor hookworm*:ti,ab,kw or hookworm*:ti,ab,kwor ancylostoma*:ti,ab,kw or
cestode*:ti,ab,kw or tapeworm*:ti,ab,kw or tape worm*:ti,ab,kw or trematode*:ti,ab,kw or fluke*:ti,ab,kw or whipworm*:
ti,ab,kw or whip worm*:ti,ab,kw or trichuris:ti,ab,kw or ascaris:ti,ab,kw or enterobi*:ti,ab,kw or strongyloide*:ti,ab,kw or
mansonell*:ti,ab,kw or taenia:ti,ab,kw schistosom*:ti,ab,kw or necator*:ti,ab,kw or paragonim*:ti,ab,kw or hymenolepis:
ti,ab,kw or fasciol*:ti,ab,kw or filariasis:ti,ab,kw or trichostrongl*:ti,ab,kw or microfilaria:ti,ab,kw or [mh ˆ“parasitic
diseases”] or [mh helminthiasis] or [mh ˆ“intestinal diseases, parasitic”] (Word variations have been searched)
#8 benzimidazoles or albendazole or mebendazole or ivermectin or praziquantel or diethylcarbamazine or bithionol or ox-
amniquine or pyrantel or nitazoxanide or anthelmintic or anthelmintics or anthelminthic or anthelminthics or “anti
helminthic” or “anti helminthics” or “anti helmintic” or “anti helmintics” or antihelminthic or antihelminthics or anti-
helmintic or antihelmintics (Word variations have been searched)
#9 #6 and #7 and #8 Publication Year from 1980 to 2015, in Trials
Table 4. Cochrane librarian search strategy for the WHO ICTRP
Number Search terms
#1 HIV AND HELMINTH
Table 5. Cochrane librarian search strategy for clinicaltrials.gov
Number Search terms
#1 HIV AND HELMINTH | Interventional Studies | received from 01/01/1980 to 09/29/2015
Table 6. Search terms used in 2009 newly applied in MEDLINE
Number Search terms
#1 “HIV Infections”[MeSH] OR “HIV”[MeSH] OR hiv [tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR
hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficiency virus[tw] OR human immunod-
eficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR ac-
quired immunodeficiency syndrome[tw] OR acquired immunedeficiency syndrome[tw] OR acquired immunodeficiency
syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw])
) OR “Sexually Transmitted Diseases, Viral”[MeSH:NoExp]
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Table 6. Search terms used in 2009 newly applied in MEDLINE (Continued)
#2 randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random
allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials
[mh] OR (“clinical trial” [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR
blind* [tw])) OR (placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative
study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR
prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT human [mh])
#3 HELMINTHS OR ROUNDWORM OR ROUND WORM OR ROUND-WORM OR ROUNDWORMS OR
ROUNDWORMSOR ROUND-WORMS ORNEMATODESORNEMATODEOR CESTODEOR CESTODES
OR TAPEWORM OR TAPE WORM OR TAPE-WORM OR TAPEWORMS OR TAPE WORMS OR TAPE-
WORMS OR TREMATODE OR TREMATODES OR FLUKE OR FLUKES ORWORMORWORMS OR PARA-
SITE OR PARASITES OR ASCARIS ORTRICHURIS OR ENTEROBIUS OR STRONGYLOIDE OR STRONGY-
LOIDES OR ANCYLOSTOMA OR ANCYLOSTOMAS OR NECATOR OR NECATORS OR HYMENOLEPIS
OR PARAGONIMUS OR FASCIOLA OR TAENIA OR HOOKWORMORHOOKWORMORHOOK-WORM
OR HOOKWORMS OR HOOK WORMS OR HOOK-WORMS OR WHIPWORM OR WHIP WORM OR
WHIP-WORMORWHIPWORMSORWHIPWORMSORWHIP-WORMSORSCHISTOSOMIASISORMAN-
SONELLA OR FILARIASIS OR MICROFILARIA OR TRICHOSTRONGYLUS OR TRICHOSTRONGYLOSIS
OR STRONGYLOIDEA OR PARAGONIMIASIS
#4 BENZIMIDAZOLES OR ALBENDAZOLE ORMEBENDAZOLE OR IVERMECTIN OR PRAZIQUANTEL OR
DIETHYLCARBAMAZINE OR BITHIONOL OR OXAMNIQUINE OR PYRANTEL OR NITAZOXANIDE
#5 #3 AND #4
#6 #1 AND #2 AND #5
#7 #1 AND #2 AND #5 Limits: Publication Date from 1980 to 2015/09/29
Table 7. Search terms used in 2009 newly applied in EMBASE
Number Search terms
#1 ((’human immunodeficiency virus infection’/exp OR ’human immunodeficiency virus infection’) OR (’human immun-
odeficiency virus infection’/exp OR ’human immunodeficiency virus infection’)) OR ((’human immunodeficiency virus’/
exp OR ’human immunodeficiency virus’) OR (’human immunodeficiency virus’/exp OR ’human immunodeficiency
virus’)) OR (hiv:ti OR hiv:ab) OR (’hiv-1’:ti OR ’hiv-1’:ab) OR (’hiv-2’:ti OR ’hiv-2’:ab) OR (’human immunodefi-
ciency virus’:ti OR ’human immunodeficiency virus’:ab) OR (’human immuno-deficiency virus’:ti OR ’human immuno-
deficiency virus’:ab) OR (’human immunedeficiency virus’:ti OR ’human immunedeficiency virus’:ab) OR (’human im-
mune-deficiency virus’:ti OR ’human immune-deficiency virus’:ab) OR (’acquired immune-deficiency syndrome’:ti OR
’acquired immune-deficiency syndrome’:ab) OR (’acquired immunedeficiency syndrome’:ti OR ’acquired immunedefi-
ciency syndrome’:ab) OR (’acquired immunodeficiency syndrome’:ti OR ’acquired immunodeficiency syndrome’:ab) OR
(’acquired immuno-deficiency syndrome’:ti OR ’acquired immuno-deficiency syndrome’:ab)
#2 random:ti OR random:ab OR factorial:ti OR factorial*:ab OR ’cross over’:ti OR ’cross over’:ab OR crossover:ti OR
crossover:ab OR placebo:ti OR placebo:ab OR (double:ti AND blind:ti) OR (doubl:ab AND blind*:ab) OR (single:ti
AND blind:ti) OR (single:ab AND blind:ab) OR assign:ti OR assign:ab OR allocat:ti OR allocate:ab OR volunteer:ti
OR volunteer:ab OR ’crossover procedure’/exp OR ’crossover procedure’ OR ’double-blind procedure’/exp OR ’double-
blind procedure’ OR ’single-blind procedure’/exp OR ’single-blind procedure’ OR ’randomized controlled trial’/exp OR
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Table 7. Search terms used in 2009 newly applied in EMBASE (Continued)
’randomized controlled trial’
#3 ’helminths’ OR ’roundworm’ OR ’round worm’ OR ’round-worm’ OR roundworms OR ’round worms’ OR ’round-
worms’ OR nematodes OR ’nematode’ OR ’cestode’ OR cestodes OR ’tapeworm’ OR ’tape worm’ OR ’tape-worm’
OR tapeworms OR ’tape worms’ OR ’tape-worms’ OR ’trematode’ OR trematodes OR ’fluke’ OR flukes OR ’worm’
OR worms OR ’parasite’ OR ’parasites’ OR ’ascaris’ OR ’trichuris’ OR ’enterobius’ OR strongyloide OR stronglyloides
OR ’ancylostoma’ OR ancylostomas OR ’necator’ OR necators OR ’hymenolepis’ OR ’paragonimus’ OR ’fasciola’ OR
’taenia’ OR ’hookworm’ OR ’hook worm’ OR ’hook-worm’ OR hookworms OR ’hook worms’ OR ’hook-worms’ OR
’whipworm’ OR ’whip worm’ OR ’whip-worm’ OR whipworms OR ’whip worms’ OR ’whip-worms’ OR shistosomiasis
OR ’mansonella’ OR ’filariasis’ OR ’microfilaria’ OR ’trichostrongylus’ OR trichostronglylosis OR stronglyloidea OR
pargonimiasis
#4 ((’benzimidazoles’/expOR ’benzimidazoles’)OR (’benzimidazoles’/expOR ’benzimidazoles’))OR ((’albendazole’/expOR
’albendazole’) OR (’albendazole’/expOR ’albendazole’))OR ((’mebendazole’/expOR ’mebendazole’)OR (’mebendazole’/
expOR ’mebendazole’))OR ((’ivermectin’/expOR ’ivermectin’)OR (’ivermectin’/expOR ’ivermectin’))OR ((’praziquan-
tel’/exp OR ’praziquantel’) OR (’praziquantel’/exp OR ’praziquantel’)) OR ((’diethylcarbamazine’/exp OR ’diethylcarba-
mazine’) OR (’diethylcarbamazine’/exp OR ’diethylcarbamazine’)) OR ((’bithionol’/exp OR ’bithionol’) OR (’bithionol’/
exp OR ’bithionol’)) OR ((’oxamniquine’/exp OR ’oxamniquine’) OR (’oxamniquine’/exp OR ’oxamniquine’)) OR (
(’pyrantel’/exp OR ’pyrantel’) OR (’pyrantel’/exp OR ’pyrantel’)) OR ((’nitazoxanide’/exp OR ’nitazoxanide’) OR (’ni-
tazoxanide’/exp OR ’nitazoxanide’))
#5 #3 OR #4
#6 #1 AND #2 AND #5 [1-1-1980]/sd NOT [29-09-2015]/sd
Table 8. Search terms used in 2009 newly applied in CENTRAL
Number Search terms
#1 (HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*)
OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HU-
MAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IM-
MUN*) AND (DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME) OR (AC-
QUIRED IMMUNEDEFICIENCY SYNDROME)OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME)OR
(ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED IMMUN*) AND (DEFICIENCY SYN-
DROME)) OR (VIRAL SEXUALLY TRANSMITTED DISEASES)
#2 HELMINTHS OR ROUNDWORM OR ROUND WORM OR ROUND-WORM OR ROUNDWORMS OR
ROUNDWORMSORROUND-WORMSORNEMATODESORNEMATODEORCESTODEORCES-TODES
OR TAPEWORM OR TAPE WORM OR TAPE-WORM OR TAPEWORMS OR TAPE WORMS OR TAPE-
WORMS OR TREMATODE OR TREMATODES OR FLUKE OR FLUKES ORWORMORWORMS OR PARA-
SITE OR PARASITES OR ASCARIS ORTRICHURIS OR ENTEROBIUS OR STRONGYLOIDE OR STRONGY-
LOIDES OR ANCYLOSTOMA OR ANCYLOSTOMAS OR NECATOR OR NECATORS OR HYMENOLEPIS
OR PARAGONIMUS OR FASCIOLA OR TAENIA OR HOOKWORMORHOOKWORMORHOOK-WORM
OR HOOKWORMS OR HOOK WORMS OR HOOK-WORMS OR WHIPWORM OR WHIP WORM OR
WHIP-WORMORWHIPWORMSORWHIPWORMSORWHIP-WORMSORSCHISTOSOMIASISORMAN-
SONELLA OR FILARIASIS OR MICROFILARIA OR TRICHOSTRONGYLUS OR TRICHOSTRONGYLOSIS
OR STRONGYLOIDEA OR PARAGONIMIASIS
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Table 8. Search terms used in 2009 newly applied in CENTRAL (Continued)
#3 BENZIMIDAZOLES OR ALBENDAZOLE ORMEBENDAZOLE OR IVERMECTIN OR PRAZIQUANTEL OR
DIETHYLCARBAMAZINE OR BITHIONOL OR OXAMNIQUINE OR PYRANTEL OR NITAZOXANIDE
#4 #2 OR #3
#5 #1 AND #4 from 1980 to 2015
Table 9. Search terms used in 2009 newly applied in AIDSEARCH
Number Search terms
#1 (HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*)
OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HU-
MAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IM-
MUN*) AND (DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME) OR (AC-
QUIRED IMMUNEDEFICIENCY SYNDROME)OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME)OR
(ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED IMMUN*) AND (DEFICIENCY SYN-
DROME)) OR (SEXUALLY TRANSMITTED DISEASES, VIRAL)
#2 ((RANDOMIZED CONTROLLED TRIAL) OR (CONTROLLED CLINICAL TRIAL) OR (RANDOMIZED
CONTROLLED TRIALS) OR (RANDOM ALLOCATION) OR (DOUBLE-BLIND METHOD) OR (SINGLE-
BLIND METHOD) OR (CLINICAL TRIAL) OR (CLINICAL TRIALS) OR (“CLINICAL TRIAL”) OR ((SINGL*
OR DOUBL* OR TREBL* OR TRIPL* AND (MASK* OR BLIND*)) OR PLACEBOS OR PLACEBO* OR
RANDOM* OR (COMPARATIVE STUDY) OR (EVALUATION STUDIES) OR (FOLLOW-UP STUDIES) OR
(PROSPECTIVE STUDIES) OR CONTROL* OR PROSPECTIV* OR VOLUNTEER*)) NOT (ANIMALS NOT
HUMAN)
#3 #1 AND #2
#4 HELMINTHS OR ROUNDWORM OR ROUND WORM OR ROUND-WORM OR ROUNDWORMS OR
ROUNDWORMSORROUND-WORMSORNEMATODESORNEMATODEORCESTODEORCES-TODES
OR TAPEWORM OR TAPE WORM OR TAPE-WORM OR TAPEWORMS OR TAPE WORMS OR TAPE-
WORMS OR TREMATODE OR TREMATODES OR FLUKE OR FLUKES ORWORMORWORMS OR PARA-
SITE OR PARASITES OR ASCARIS ORTRICHURIS OR ENTEROBIUS OR STRONGYLOIDE OR STRONGY-
LOIDES OR ANCYLOSTOMA OR ANCYLOSTOMAS OR NECATOR OR NECATORS
#5 HYMENOLEPIS OR PARAGONIMUS OR FASCIOLA OR TAENIA OR HOOKWORM OR HOOK WORM
OR HOOK-WORM OR HOOKWORMS OR HOOK WORMS OR HOOK-WORMS OR WHIPWORM OR
WHIP WORM OR WHIP-WORM OR WHIPWORMS OR WHIP WORMS OR WHIP-WORMS OR SCHIS-
TOSOMIASIS ORMANSONELLAOR FILARIASIS ORMICROFILARIA ORTRICHOSTRONGYLUS ORTRI-
CHOSTRONGYLOSIS OR STRONGYLOIDEA OR PARAGONIMIASIS
#6 BENZIMIDAZOLES OR ALBENDAZOLE ORMEBENDAZOLE OR IVERMECTIN OR PRAZIQUANTEL OR
DIETHYLCARBAMAZINE OR BITHIONOL OR OXAMNIQUINE OR PYRANTEL OR NITAZOXANIDE
#7 #4 OR #5 OR #6
#8 #7 AND #3
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Table 10. Search strategy for the WHO Global Health Library
Number Search terms
#1 Helminth* AND “HIV Infections” received from 01/01/1980 to 09/29/2015
Table 11. Characteristics of trials in which participants had unknown helminth infection status
Trial Country Setting Year enrol-
ment com-
pleted
Inclusion
criteria
Age Total ran-
domized
Number
HIV-posi-
tive partic-
ipants
Taking
ART
Num-
ber co-in-
fected
with
helminths
at baseline
Kelly 1996
ZMB
Zambia Urban Not stated HIV-
infected
adults with
persistent
diarrhoea
> 18 years 174 174 Not stated
(probably
low)
Unknown
Webb
2012UGA
Uganda Urban 2005 HIV-
infected
pregnant
women
Not stated 264 264 < 3% 67%
had at least
1 helminth
species
Walson
2012 KEN
Kenya Urban/
rural
2011 HIV-in-
fected, not
on ART
> 18 years 948 948 None at
baseline
Unknown
Abbreviations: HIV: human immunodeficiency virus; ART: antiretroviral.
Table 12. Description of interventions
Trial Intervention Control Outcomes Timing
Drug Dose Frequency
Walson 2008
KEN
Albendazole 400 mg Once daily for 3
days
Placebo Viral load
CD4
Adverse events
Mortality events
12 weeks
Abate 2014
ETH
Albendazole 400 mg Once daily for 3
days
Placebo CD4
Adverse events
Mortality events
12 weeks
Kallestrup 2005
ZWE
Praziquantel 40 mg/kg Once only No intervention Viral load
CD4
12 weeks
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Table 12. Description of interventions (Continued)
Nielsen 2007
TZA
Diethylcarba-
mazine
6 mg/kg Once only Placebo Viral load
CD4
Adverse events
12 weeks
Kelly 1996 ZMB Albendazole 800 mg Twice daily for
14 days
Placebo Adverse events
Mortality events
6 months
Suputtamongkol
2011 THA
Ivermectin 200 mg/kg Single or dou-
ble dose 2 weeks
apart
Albendazole Adverse events 1 year
Webb 2012
UGA
Albendazole
Praziquantel
400 mg
40 mg/kg
Once only
Once only
Placebo Viral load
Adverse events
Mortality events
6 weeks
Walson 2012
KEN
Albendazole
Praziquantel
400 mg
25 mg/kg
Every 3 months
Annually
No intervention Viral load
CD4
Adverse events
Mortality events
2 years
Table 13. Characteristics of trials in which participants had confirmed helminth infections
Trial Country Setting Year
enrolment
completed
Inclusion
criteria
Age Total ran-
domized
Number
of HIV-
pos-
itive par-
ticipants
Taking
ART
Num-
ber co-in-
fected
with
helminths
at baseline
Walson
2008
KEN
Kenya Urban/
rural
2007 HIV-in-
fected with
at least one
helminth
co-
infection
> 18 years 234 234 None at
baseline
All
Abate
2014
ETH
Ethiopia Urban 2012 Newly di-
agnosed
TB partici-
pants with
helminth
co-
infection
15 to 60
years
140 32 94% of in-
terven-
tion group,
100% of
controls
All
Kallestrup
2005
ZWE
Zimbabwe Rural 2003 Adults in-
fected with
schistoso-
miasis
> 18 years 287 130 Not stated All
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Table 13. Characteristics of trials in which participants had confirmed helminth infections (Continued)
Nielsen
2007 TZA
Tanzania Rural 2002 HIV-
infected
adults
22 to 70
years
34 34 Not stated 18
Suputta-
mongkol
2011
THA
Thailand Urban 2009 Adults
with char-
acteristic
strongy-
loides
infection
> 18 years 100 10 Not stated All
Abbreviations: HIV: human immunodeficiency virus; ART: antiretroviral; TB: tuberculosis.
Table 14. Ongoing or planned RCTs
Trial name Relevant interven-
tion
Relevant outcome Target population Location(s) Estimated comple-
tion date
Reduction of EArly
mortaLITY inHIV-
infected Adults and
Children Starting
Antiretroviral Ther-
apy (REALITY)
Immediate en-
hanced opportunis-
tic
infections (OI) pro-
phylaxis with isoni-
azid/pyridoxine and
cotrimoxazole, plus
12 weeks flucona-
zole, 5 days azithro-
mycin, and a sin-
gle dose of alben-
dazole versus cot-
rimoxazole prophy-
laxis alone for the
first 12 weeks fol-
lowed by isoniazid
and any prophy-
laxis and/or treat-
ment prescribed at
screening
• Change in CD4
count
• Adverse events
HIV-infected indi-
viduals ages ≥ 5
years
Kenya, Malawi,
Uganda, Zimbabwe
February 2016
Can Anthelminthic
Treat-
ment Delay the Pro-
gression of HIV?
Randomised Open-
label Trial Testing
Presump-
tive Anthelminthic
Treatment on
Standard HIV care
with provision of
praziquantel, alben-
dazole, and iver-
mectin at baseline,
after 6 months, and
after 12 months ver-
sus standard
HIV care with no
• Change in viral
load
• Change in CD4
count
• Adverse event
HIV-infected indi-
viduals aged ≥ 18
years
Tanzania Terminated prema-
turely due to recruit-
ment difficulties
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Table 14. Ongoing or planned RCTs (Continued)
Progression of HIV
in ART-naïve HIV-
positive Patients in
a Rural African Set-
tingWith Presumed
High Prevalence
of Helminth Infec-
tions
anthelminthic treat-
ment
Abbreviations: RCT: randomized controlled trial; HIV: human immunodeficiency virus; ART: antiretroviral.
WH A T ’ S N E W
Date Event Description
11 April 2016 New citation required and conclusions have changed In this review update we included eight trials: three were in
the 2009 version of this Cochrane review,Walson 2009, and
we included five new trials. We assessed the quality of the
evidence using GRADE criteria, and produced ’Summary
of findings’ tables
11 April 2016 New search has been performed We included eight trials in this review update. Bradley R
Herrin and Grace John-Stewart stepped down from the re-
view author team, and Arianna Rubin Means, Paul Burns,
and David Sinclair joined the review author team. We
amended the title of this review from ’Deworming helminth
co-infected individuals for delaying HIV disease progres-
sion’ to ’Antihelminthics in helminth-endemic areas: effects
on HIV disease progression’
H I S T O R Y
Date Event Description
19 August 2014 Amended Update started.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In this review update we utilized the GRADE criteria, produced ’Summary of findings’ tables, and stratified outcomes according to
whether HIV-positive participants had confirmed helminth infections or were of unknown helminth infection status.
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